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Abstract 
 
 
A better understanding of the rate and extent for oral drug product dissolution in the 
gastrointestinal (GI) tract can provide an invaluable perspective in the drug development process. 
As it is difficult to experimentally measure the rate and extent of dissolution, the purpose of this 
research is to develop a validated model-based method that translates clinically observed plasma 
profiles into predictions of in vivo dissolution with validation by GI drug concentration profiles. 
The resulting model was based on physiologically considerations such as series-based transit, 
fluid volume, mucus layer, and pH to model the oral absorption process.  
Local GI fluid volume was identified as a poorly characterized physiological variable that 
essential in modeling local GI drug concentrations, thereby influencing the simulation of drug 
dissolution and absorption. A dynamic fluid transport model was developed from GI fluid 
volumes found in literature with validation based on transport of a non-absorbable marker. The 
simulation found volumes in the GI tract to vary more in the upper than later GI and more at 
earlier timepoints than later timepoints. The simulation also found faster drug transit that 
reflected the earlier larger volumes followed by slower transit when volume is limited, 
explaining the observed extended residence time of drug in the stomach and small intestine 
environments.  
To predict the rate and extent of in vivo drug dissolution, an algorithm based 
deconvolution of human plasma profile after 800 mg ibuprofen dose was deployed using the 
developed mechanistic model with the addition of a two-compartment pharmacokinetic model. 
xiv 
 
Consideration of gastric emptying lag time was essential to validating the simulated and 
experimental in vivo GI concentration profile of ibuprofen observed in a recent clinical study 
where lag time was determined by rapid rise of ibuprofen in plasma that reflects its significantly 
higher solubility in the small intestine pH environment. The simulation predicted minimal 
dissolution (2%) in the stomach, rapid but short dissolution in the duodenum (6.3%), core 
dissolution in the jejunum (63%) over 210 minute period, and completion of dissolution in the 
ileum (25%). 
To further obtain reference data for evaluation of in vivo dissolution, a clinical study was 
conducted that found extended residence time mesalamine in the GI tract for modified release 
formulations. To model the extended residence time of mesalamine drug in the stomach, the 
deconvolution algorithm was applied to human plasma profile after 1000 mg dose of Pentasa 
using the developed mechanistic model with the addition of a two-compartment pharmacokinetic 
model. The characterization of bio-adherence from excipients used in the formulation was 
incorporated in the mechanistic oral absorption model by establishing additional mucus 
compartments where particles would “attach” and experience slower transit due to mucus. The 
simulation produced local GI drug concentrations similar in magnitude to the clinically observed 
profiles with extended residence past 7 hours.  
The acquisition of local GI concentration profiles played a critical role in developing in 
vivo dissolution models with validation. The data further suggests that quantification of dynamic 
GI fluid and consideration of GI mucus can not only play an essential role in transit and 
absorption of solubilized drug, but also be a contributing factor to the transit and regional 
dissolution of drug particles. The resulting in vivo dissolution profile may be key to developing 
in vivo relevant in vitro dissolution studies. 
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Chapter 1 Introduction 
 
 
 
Computational modeling and simulation of oral drug absorption in the gastrointestinal 
tract has been used to address numerous scientific questions with the potential to change the drug 
development and approval process (1). When successful, oral absorption models have 
contributed significantly to the drug development process in areas such as lead drug candidate 
selection, formulation development strategies, and development of regulatory policies (2). 
Despite numerous models being developed to characterize oral drug product dissolution 
and absorption in the GI, these models often have instances of limited predictive value (3). One 
of the major challenges to constructing models that offer improved prediction capabilities is 
providing an accurate assessment of the system to ensure high quality model input (4).  
The traditional focus of improving oral absorption models has focused extensively on the 
physiochemical aspects of drug compounds such as pKa, GI pH, solubility, particle size, crystal 
form, and salt diffusivity (2). However, the in vivo behavior of a drug product is reliant not only 
on these physiochemical properties but also the local available fluid volume. By association, the 
dynamic nature of GI fluid volume and corresponding transport can greatly affect the dissolution 
and absorption of oral drug products (5). 
Model based evaluation have demonstrated intestinal water volumes to have a large 
impact on the predictive power of simulations to correctly model mean plasma concentration 
profiles (6). As local GI fluid content is the medium for drug dissolution and absorption, an 
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improvement in the physiologically characterization of GI fluid volume is a critical opportunity 
to improve the foundation of mechanistic oral absorption models.  
This introduction reviews the current integration of GI fluid considerations in 
mechanistic oral absorption models, the conceptualization of fluid in in vivo dissolution 
equations, and recent imaging based studies that can experimentally determine GI fluid volume 
through non-invasive means. Combined, these sources form a new basis for mechanistic 
modeling of GI fluid in in vivo absorption and dissolution.  
Mechanistic Oral Absorption Models 
Current mechanistic oral absorption models are based on a series of Continuously Stirred 
Tank Reactors (CSTRs) first popularized by the Compartment Absorption and Transport (CAT) 
model (2, 7). The model was comprised of 7 compartments in series with an assumed first order 
transit and first order absorption. Because the primary dose considered was a solution dosing, the 
model approximated absorption to be mass driven. While this approach proved to be a sufficient 
approach to model oral absorption, the limited considerations resulted in a model that was 
difficult to integrate in vivo dissolution.  
Numerous models have since been published that expanded the mechanistic 
compartments used in the CAT model approach to include considerations for solid, particle, and 
dissolved drug states. In combination with new basis for GI fluid volumes, the mechanistic 
expansion allowed for predicted absorption and/or dissolution. In addition, these models also 
expand beyond GI fluid volumes with numerous physiological considerations and complex 
mechanisms such as segmental residence times (3, 8). Three of these models are discussed in 
further detail: Advanced Compartment Absorption and Transport (ACAT) and Advanced 
Dissolution Absorption and Metabolism (ADAM), and GI-Sim (9-11).  
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Advanced Compartment Absorption and Transport Model 
The ACAT model was the first compartmental model to expand the single serial 
compartment of the CAT approach into three unique compartments as a method to characterize 
the solid, particle, and dissolved states drug phases (Figure 1). The ACAT model defined oral 
drug absorption by Equation 1 (9).  
 absorption(") = 𝑘(")&𝑉(")(𝐶(")* − 𝐶("),- (1)  
Where absorption(") is the absorption rate, 𝑘(")& is the absorption rate constant for compartment 𝑖	, 𝑉(") is the volume of compartment 𝑖, 𝐶(")* is the lumen concentration and 𝐶("), is the 
concentration in enterocyte. Through this approach, the ACAT could make considerations for the 
available fluid volume and local drug concentration when calculated absorption.  
 
Figure 1. ACAT model schematic. (reproduced) (9) 
The volume term used in the ACAT model is a static volume and does not represent the 
changing environment of the GI tract and as such, ensures that the driving gradient for absorption 
is generally dependent on the amount of drug available in the GI tract. Based using this 
approach, the ACAT model could replicated with absolutely certainty the results obtained by the 
CAT model. In addition, the addition of volume terms allowed the ACAT model to be 
customized with regional variations that allowed for better model fitting when evaluating the 
absorption process. 
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In addition, the physiology of the GI tract was approximated in the ACAT model with the 
length, transit time, and radii of the intestine environment was based on published values (12). 
However, when the actual fluid volumes used in the ACAT model are compared with 
experimental results, the default volume settings for the small intestine needed to be reduced by 
60% and the colon by 90% (13). If these volumes are directly used to simulate dissolution and 
absorption, the availability of more than double the local GI fluid volume limits the realistic 
predictive value of the model.   
While it is unclear how the fluid volumes used in the model were determined, predictive 
methodology of the ACAT model is confounded using an artificial scale factor (ASF). The ASF 
term is a coefficient that encapsulates inter-compartment variation such as surface-to-volume 
ratio, pH effects, influx, or efflux transporter differences, and other absorption-rate-determining 
effects (14). This term mathematically minimizes the importance of well characterized GI fluid 
volumes [as input which not well defined] and functions as an additional modeling layer. The 
resulting model can be fit to any plasma profile based on adjustments to coefficient values (15).  
Advanced Dissolution Absorption and Metabolism  
The ADAM model continues the use of three states to define drug in the small intestine 
as a solid, particle and dissolved drug (Figure 2).  
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Figure 2. ADAM Model Schematic Slide (reproduced) (16) 
 
The criticality of the changing volume due to fluid intake, secretion, and absorption was 
recognized in the development of the ADAM model as an important consideration that is ignored 
in many models of oral drug absorption (10). To calibrate the model’s use of physiologically 
relevant GI fluid volumes, the GI fluid volumes were based on a water-sensitive magnetic 
resonance imaging (MRI) to define the volume of each compartment (10). Despite this however, 
the ADAM model’s ordinary differential equation does not appear to consider fluid volume in 
defining absorption (Equation 2).   
 d0D,n
d1 = d0diss,nd1 − (𝑘deg,2 + ka2 + 𝑘t,2-𝐴D,2 + 𝑘t,2-1𝐴D,2-1 + 𝛾2CLuint-T,2 fugut𝐶ent,2 (2) 
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Where 𝐴6,2 is the amount of dissolved drug in compartment 𝑛,  𝐴diss refers to the dissolution rate 
term, kdeg,n and kan are the drug degradation (luminal) and absorption rate constants, 𝑘t is the 
transit rate, γn is a unit adjustment factor for the amount of drug transported out of the enterocyte, 
fugut is the fraction of drug unbound in the enterocyte,  and CLuint-T,n and CLuint-G,n are the net 
efflux clearance from the enterocyte and net metabolic clearance within the enterocyte.  
In this approach, the absorption of the drug from the GI tract is limited to a first order rate 
constant ka2 and dependent on the amount of dissolved drug in the compartment 𝐴D. This 
conceptualization is consistent with the mass-driven CAT model as well as the ACAT model 
after excluding the pseudo concentration consideration. While availability of fluid data presents a 
valuable opportunity to consider fluid in model concentration driven absorption, the lack of 
inclusion ensures model parity and similarity with existing approaches.  
In addition to characterization fluid volumes, the ADAM model incorporates extensive 
physiological data such as gastric emptying of solids and GI pH. Where the original CAT model 
focused on characterization of solution residence in the stomach, the ADAM’s simulation of  
gastric emptying for solid oral dosage forms was based on experimental data and can be assigned 
based on a Weibull distribution to allow randomization (10, 17, 18). Experimental pH data was 
also integrated based on regional data and considerations made based on food effects (19, 20). 
These considerations can be used to improve the quality of model input for dissolution equations.  
For drugs that are heavily metabolized, the ADAM model’s limited consideration of fluid 
in absorption may not be the largest factor. The ADAM model utilizes an enterocyte 
compartment that is complimentary to each intestinal compartment. The use of this compartment 
adds an additional model layer of complexity that introduces capabilities such as modeling 
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transporter effects. Analogous to how the ASF for ACAT functions, the consideration of 
enterocytes and metabolism allow for improved prediction of pharmacokinetics (21).  
GI-SIM 
The GI-Sim absorption model is one of the latest mechanistic oral absorption models to 
adopt the compartmental approach. This approach mimics the compartmentalizing of drug 
phases into solid, particles, and dissolved drug (compartment names altered) of earlier models. 
Unlike earlier models however, the GI-Sim introduces additional complexity using an aqueous 
boundary layer that can further separate absorption and the conceptualization of micelles that can 
partition dissolved drugs (Figure 3). The use of enterocyte compartments is mimicked in the GI-
Sim using a gut wall compartment. The inclusion of an aqueous boundary layer in addition to the 
gut wall creates additional parameterization that can be further used to fit predictions similar to 
the ASF of the ACAT model.  
 
Figure 3. A schematic view of the absorption model GI-Sim. To the left a representation of the 
processes occurring in each compartment is shown. To the right, the nine ideal GI-compartments 
of the gastrointestinal tract linked with first pass effects and a pharmacokinetic two-
compartmental model is shown (reproduced) (11) 
8 
 
The physiological parameters for volume, transit times, and pH in the intestine were adopted 
from Heikkinen et al (22). The source of the physiological parameters used was stated to 
originate from the ACAT model. The GI-Sim model incorporates a slightly different approach by 
characterizing the fraction of absorption.  
 𝐹&:;<=>1"<2 = 𝑃 ∙ 𝐶: ∙ 𝑆𝐴 (3) 
Where 𝐹&:;<=>1"<2 is the mass transport of free dissolved API molecules, 𝑃	is the permeability, 𝐶: is the bulk concentration, and 𝑆𝐴 is the available surface area for absorption. In this approach, 
the degree of absorption is a function of drug characteristics and local drug concentration. As the 
surface area does not change, this conceptualization of absorption assumes it to be entirely 
dependent on the local concentration which is a reasonable approximation of a first order 
mechanism. While the concentration term includes a bulk concentration term, the presentation as 
a static term makes the default assumption that the concentration is unchanging.  
Dissolution Equations  
For solid oral dosage forms, dissolution is one of the components that determine the 
bioavailability resulting from the oral absorption process. As dissolution is a highly complex 
process, mathematical characterization of dissolution equations simplifies the complexity into 
key variables. These considerations can include the concentration in the local environment, the 
solubility of the compound, and the diffusion coefficient of the molecule. When combined with 
physiologically based oral absorption models, dissolution equations can support the prediction of 
drug dissolution in the GI tract (23). The application of these models can also be used to guide in 
vitro assay development (15). Given the implications of being able to predict oral absorption, 
physiologically meaningful dissolution equations represent a highly valuable source of insight to 
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guide drug development. In this review, the Noyes-Whitney, Nernst-Brunner, and Wang-
Flanagan equations are explained in further detail. 
Noyes-Whitney Dissolution Equation 
The Noyes-Whitney equation is a mass based differential equation to characterize the 
dissolution process (Equation 4) (24).  
 BCB1 = 𝐶(𝑆 − 𝑥) (4) 
The dissolution rate is dependent on a pre-determined solubility value 𝑆, the remaining mass in 
formulation 𝑥, and the local concentration (𝐶). Based on the terms used in the equation, the 
equation is a reasonable reflection of an instantaneous rate of dissolution as the local 
concentration term is static. Alternatively, the equation also suffices if the proportional rate of 
change of drug mass is significantly larger than the rate of change for concentration. Regardless 
of approach, both assumptions reflect the consideration of a concentration term which inherently 
incorporates a volume.  Therefore, a volume term is key to determining the released 
concentration of drug as well as the resulting dissolution rate.  
Nernst-Brunner Dissolution Equation 
The Nernst-Brunner equation expands on the Noyes-Whitney concept by incorporating 
consideration of diffusivity and a boundary layer (Equation 5) (25). 
 BEB1 = 6FGH (𝐶F − 𝐶) (5) 
Despite being written as a differential of concentration, the equation incorporates a static volume 
term which suggests that the equation is like the Noyes-Whitney equation as primarily a mass 
based-differential equation. The presence of a volume term however, suggests recognition that 
volume is a key part in determining the released concentration of drug as well as resulting 
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dissolution rate. Other key considerations in the equation include the diffusivity of the drug as 
well as the boundary layer dimensions. This represents additional insight that physical transport 
rate limitations of the drug molecule itself is also key in calculating dissolution.   
Wang and Flanagan Dissolution Equation 
The Wang and Flanagan dissolution equation is a mass based differential focused on the 
dissolution based on particle physics (Equation 6) (10, 26)..  
 B0IJKK,LB1 = −4𝜋𝑟P(𝑡)𝐷 S T=(1) + THU V𝐶F,2 − 0W,LGlumen,L(X)Y (6) 
One of the key assumptions in this equation is that the rate of dissolution is solely dependent on 
the gradient between peak solubility and the exist concentration. Like the Nernst-Brunner, the 
equation has separated the volume term and has recognized volume to be a major contributing 
term to the dissolution rate. Additional considerations primarily focus on expanding the 
characterization of diffusion and boundary layer to be a function of the available surface area of 
the drug. In this equation, the radius of the particle is assumed to be dynamic and shrinking over 
time with a constant boundary layer thickness.  
Volume Considerations 
The approach by these dissolution equations incorporate inherent recognition that the 
available local volume plays a role in determining the rate. The Noyes-Whitney equation 
accomplished this by embedding volume in the concentration term. Both the Nernst-Brunner and 
Wang-Flanagan equation clarified the local GI volume with an independent term. A key 
difference between these equation is temporal consideration of local volume. Only the Wang-
Flanagan equation considered the local GI volume to be dynamic which subsequently can 
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modify the dissolution rate. This represents a closer attempt at capturing the contributing factors 
to in vivo dissolution.  
Imaging Based Quantification of Gastrointestinal Volume 
The basis of current mechanistic oral absorption models have focused on a primarily 
mass based approach to predict oral absorption. This was reasonably established on the basis of 
the results obtained by the CAT model. However, there is a recognized need for better model 
input to improve predicative capabilities. For mechanistic gastrointestinal models, this lies in 
determining accurate local GI fluid volume to calculate local GI drug concentrations for 
absorption.  As such, GI fluid volume is a major focal point for the ACAT, ADAM, and GI-Sim 
models with the reference values used in each model listed in Table I  (8). 
Each commercialized software package has utilized different numerical values for GI 
fluid volumes. The degree of variation between the models, however, is significant.  The total of 
all the compartments used (at the time referenced) is 205mL in the ADAM model which is 
comparable with just one compartment in the ACAT model at 175mL.  
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Table 1. Comparison of fluid volumes used in oral absorption models (reproduced) (8). 
GI 
COMPARTMENT 
SIMCYP 
(ADAM) 
GASTROPLUS 
(ACAT) 
GI-SIM 
1 53 50 47 
2 35 48 42 
3 24 175 150 
4 24 140 120 
5 14 109 94 
6 14 79 71 
7 14 56 50 
8 14 53  
9 13 57  
 
The quantification of GI fluid volumes to improve physiological relevance have been 
primarily based on two imaging technologies: Magnetic Resonance Imaging (MRI) which 
incorporates a magnetic field and pulses of radio waves to create pictures of organs and 
structures inside the body and Position Emission Topography (PET) which uses the emission of 
photos from radiolabeled markers to determine volume (27-29). 
The quantification of GI fluid used in the ADAM and GI-Sim model are based on the 
MRI study that investigated the quantity of water in the GI tract during fastest and one hour after 
a meal (27). The study observed that the fluid is not homogenously distributed along the gut 
which can contributed to the individual variability of drug absorption. Another MRI study 
involved the dosing of a standard water dosing (240mL/8oz) in fasted healthy human volunteers 
(28). Both studies obtained valuable quantification of GI fluid content that can be translated 
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directly for use in oral absorption models. It should be noted that the MRI was only able to 
capture freely mobile fluid with long transverse relaxation times resulting in fluid components 
with restricted mobility and shorter transverse relaxation times (ie. mucus) not accounted for (28, 
30). 
PET imaging technology was recently used to capture the GI absorption and bio-
distribution process (31). The study dosed humans with soft gelatin capsules containing 2-
[(18)F]fluoro-2-deoxy-D-glucose ([(18)F]FDG) and was able to estimate GI tract volume from 
PET image analysis. Unlike the MRI imaging studies however, PET imaging was dependent on a 
molecule based marker that could diffuse and cover the outer regions of the intestine. This 
resulted in quantification values that may have captured the maximum volume of the GI tract 
rather than the local GI fluid volume available for dissolution and absorption.  
Specific Aims 
The predictive capabilities of current mechanistic oral absorption models are limited by 
physiologically relative local GI fluid volumes. Through characterization of local GI fluid 
volume and application to demonstrate the value of a fluid centric approach, the specific aims for 
this project are as follows:  
1. Develop a mechanistic GI fluid transport model determines the quantity and transport of 
GI fluid volume in the GI tract 
2. Develop a mechanistic deconvolution approach that incorporates the mechanistic GI fluid 
transport model to predict in vivo dissolution 
3. Determine in vivo concentration of modified release mesalamine in human GI tract to 
improve connection with local GI fluid volume 
4. Develop a mechanistic deconvolution model that can predict drug dissolution of delayed 
release mesalamine in the human GI tract based on established GI fluid transport model 
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Chapter 2 Mechanistic Gastrointestinal Fluid Model to Determine Volume and Transport 
Over Time1 
 
Gastrointestinal (GI) fluid volume is a key factor in the dissolution and absorption 
process of oral drug products. For solid oral dosage forms, the local quantity of fluid can affect 
disintegration, dissolution, and absorption. Because local GI fluid volume varies significantly 
due to transit, secretion, and absorption, characterizing the in vivo environment is essential to 
accurately model the oral drug dissolution and absorption process. An accurate model of the oral 
drug product dissolution and absorption process can facilitate lead drug candidate selection, 
establish formulation development strategies, and support development of regulatory policies (2). 
To predict oral drug absorption, models have incorporated physiological parameters of 
the GI tract (3, 8). The Compartment Absorption and Transit (CAT) model utilized a small 
intestine mean residence time to define transit rate (7). The Advanced Compartment Absorption 
and Transit (ACAT) model utilized mass balance approximations to define each compartment’s 
volume and transit (9). The Advanced Dissolution Absorption and Metabolism (ADAM) utilized 
volumes reported by water-sensitive magnetic resonance imaging (MRI) to define the volume of 
each compartment (10).  
The Dynamic Fluid Compartment Absorption and Transport (DFCAT) model was 
developed to characterize the fluid volume and its dynamic changes in the human GI tract from 
                                               
1 Adapted by permission from Springer Customer Service Centre GmbH: Springer Nature The AAPS Journal  
Mechanistic Fluid Transport Model to Estimate Gastrointestinal Fluid Volume and Its Dynamic Change Over Time, 
Alex Yu, Trachette Jackson, Yasuhiro Tsume, Mark Koenigsknecht, Jeffrey Wysocki, Luca Marciani, Gordon L. 
Amidon, Ann Frances, Jason R. Baker, William Hasler, Bo Wen, Amit Pai, and Duxin Sun, 2017 
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MRI imaging of fluid volume and to evaluate its accuracy of in vivo fluid transport based on 
human GI local concentration of the non-absorbable maker phenol red from a human intubation 
study. The MRI study quantified the content of water in the stomach and small intestine after 
dosing healthy human volunteers with 240mL of water (8). The human intubation study 
measured local GI concentration (stomach, duodenum, proximal jejunum, middle jejunum) of 
phenol red in healthy human volunteers after dosing 240 mL water with phenol red. These two 
studies in addition to literature data served to verify and validate the DFCAT model. In future 
applications, the DFCAT model can be expanded to estimate the in vivo drug dissolution process 
and therefore predict oral drug absorption of oral drug products.  
Materials and Methods  
A mathematical model, described in detail in the following sections, was derived to 
capture the essential features of GI fluid transport. The model consists of 62 nonlinear ordinary 
differential equations (ODE). The stomach is represented by two ODEs (dissolved drug and 
fluid) with the small intestine represented by 60 ODEs representing a 30-compartment model 
(each compartment connected in series with a dissolved drug and fluid component). 30 
compartments were selected to represent the localized fluid volume as well as capture most cases 
of small bowel fluid pocket counts observed in the MRI fluid study (28). The conceptualization 
of a large number of compartments also reflects the long length vs diameter ratio of the small 
intestine representing the local physiological situation of the small fluid volumes available for 
dissolution. An illustration of the proposed compartment model and avenues of transport is 
drawn in Figure 4.  
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Figure 4. Dynamic Fluid Compartmental Absorption and Transit (DFCAT) approach to mimic 
physiologically-relevant fluid volumes and to predict corresponding transit of the gastrointestinal 
tract (compartment number denoted by subscript). 
 
Matlab 2017a was used for both the simulation of model ODEs and the prediction of rate 
coefficient parameters. A fixed step ODE solver from the Simulink Package (ODE4) was used in 
1s intervals. Calculations were run in parallel model using the parfor method. Visualized data 
graphics were rendered using Matlab’s plot and surf packages. Table 2 summarizes the 
parameters obtained and used in the model.  
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Table 2. Variable values used in the DFCAT model 
Symbol Parameter Literature 
Value 
Model 
Value 
Units Model Value 
Source 𝑘ZF Gastric emptying rate 
constant 
 0.699 min-1 Experimental fit 𝑘;F Gastric secretion rate 1.39-2.08  
mLmin-1(32) 
 
1.425 mLmin-1 Experimental fit 
𝑘;[ Duodenal secretion 
rate 
2.78 mLmin-1 
daily (33) 
0-4.5 mLmin-1 Experimental fit 𝑉:  Volume of mucus in 
the small intestine 
compartment 
200-400 µm (34-
36) 
5 mL Estimate 
𝑉:F Volume of mucus in 
the stomach 
1mm thick(37) 40 mL Estimate 𝑘1\  Small intestine transit 
rate (forward) 
199 min small 
intestine mean 
residence time 
(38) 
0.92 min-1 Literature fit 𝑘1]  Small intestine transit 
rate (reverse) 
0.269 min-1 Literature fit 𝑘&^ Small intestine water 
absorption rate 
constant 
0.0715(39) 0.0715 min-1 Literature value 
 
Stomach Compartment Fluid Compartment 
The stomach compartment is represented by one ODE for transport of fluid and one ODE 
for transport of solubilized drug. Fluid transport in the stomach was assumed to be a component 
of gastric emptying and net gastric secretion (secretion > absorption). A first order process was 
used to approximate the typical gastric emptying process (40, 41). Based on the observed trend, 
secretion on average was assumed to be constant. The result is a fluid transport ODE (Equation 
7) that is defined by a first order gastric emptying and a zero-order gastric secretion process. 
 BG_B1 = − 	𝑘ZF𝑉F	`ab
Emptying into Intestines
+ 	𝑘;F	c
Stomach Secretion
 (7) 
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𝑉F is the volume of fluid in the stomach compartment, 𝑘ZF is the first order gastric emptying rate 
constant, and 𝑘;F is zero order gastric secretion rate (Table 2).  
Stomach Compartment Dissolved Drug Compartment 
The MRI study quantified fluid as the available free water. However, it is well known 
that the stomach environment is lined with mucus which can contribute to dissolved drug 
transport. The model assumed dissolved drug equilibrated instantaneously between the mucosal 
layer and the fluid.  A mucus volume (𝑉:F) was estimated to be a static entity that lines the wall 
of the stomach but has not yet been fully quantified by clinical measurements. Mucus volume 
was estimated to be 40 mL based on a cylindrical abstraction of the stomach with an average 
capacity of 0.94L, 10cm diameter, and 1mm thick mucosal layer  (37).  
Transport of solubilized drug was assumed to follow the gastric emptying process of fluid 
based on the fraction available in free water. Drug absorption in the stomach is typically assumed 
to be negligible relative to the small intestine and as such, there is no drug absorption term for 
the stomach. Drug degradation was also assumed to be minimal. Equation 8 defines the transport 
of drug in the stomach compartment where 𝑀F is the mass of drug in the stomach compartment. 
.  
 Be_B1 = − 	𝑘ZF𝑀F S 𝑉𝑆𝑉𝑆+𝑉𝑏𝑆U	`ggggaggggb
Emptying into Intestines
 (8) 
Small Intestine Fluid Compartments 
The small intestine was represented by thirty compartments each with one ODE for 
transport of fluid and one ODE for transport of solubilized drug. Fluid transport in the small 
intestine was assumed to consist of transit, absorption, and secretion. Small intestine transit 
behavior was modeled using first order to characterize the forward (anterograde) and reverse 
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(retrograde) transit observed in human physiology (42). Water absorption was characterized by a 
deuterium-labeled water to approximate a first order absorption process with an absorption rate 
of 0.0715 min-1 (39) (Table 1). Net secretion was assumed to occur primarily in the duodenal 
region from bile and pancreatic secretions. Equation 9 defines the behavior for a small intestine 
compartment (the temporal zero order secretion term for the first compartment is not shown).  
 BGLB1h
Net Volume
= +𝑘1\𝑉2iTg`agb
Foward In
− 𝑘1\𝑉2a`b
Forward Out
+ 𝑘1]𝑉2jTg`agb
Reverse In
− 𝑘1]𝑉2a`b
Reverse Out
− 𝑘&^𝑉2`ab
Absorption
 (9) 
The forward and reverse transit rate constants are defined by 𝑘1\  and 𝑘1]  respectively. The first 
order water absorption rate constant is defined as 𝑘&^(Table	1).  
Small Intestine Dissolved Drug Compartments 
Transport of dissolved drug in the small intestine was assumed to mimic the mucosal 
behavior in the stomach compartment as various clinical studies have observed a range of 
thicknesses of the mucosal layer in the GI tract ranging from 200 to 400 µm (34-36). Based on 
an average small intestine length of 6.35m, a small intestine diameter assumption of 2.48 cm and 
an average thickness of 300 µm, the volume of the mucosal layer in the small intestine was 
estimated to be 5 mL (43, 44). The resulting Equation 10 describes the behavior of drug with 𝑀2 
as the mass of the drug presently in 𝑛 compartments. Absorption is assumed to be first order 
processes with rate coefficients of 𝑘&.  
 BeLB1q
Net Drug
= +𝑘1\𝑀2iT S GLrsGLrsjGtU`gggggagggggb
Forward In
− 𝑘1\𝑀2 S GLGLjGtU`gggagggb
Forward Out
+ 𝑘1]𝑀2jT S GLusGLusjGtU`gggggagggggb
Reverse In
− 𝑘1]𝑀2 S GLGLjGtU`gggagggb
Reverse Out
− 𝑘& vS eLGLjGtU − SewxLXyz{GI U|`gggggggagggggggb
Absorption
 (10) 
Model Verification 
The DFCAT model was fitted to the small intestine mean residence time (MRT) 
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University of Nottingham (28). The study consisted of twelve healthy and fasted individuals. 
Each individual was administered 240 mL and the subsequent GI fluid volumes were measured 
via MRI at designated intervals over 120 minutes. The variables in the model such as duodenal 
secretion was adjusted to best fit the average observed fluid over time in the study. Small 
intestine MRT distribution was obtained from existing models that aggregated clinical data (28, 
45). The inclusion of small intestine MRT in the DFCAT model mirrors a major design 
verification criteria of the original CAT model. 
Human Intubation Clinical Study for Model Validation 
The DFCAT Model was validated based on the local GI concentration acquired through a 
human clinical intubation study at the University of Michigan using the non-absorbable marker 
phenol red.  
Ethics Statement 
The study was approved by University of Michigan IRBMED HUM00085066 and the 
Food and Drug Administration (RIHSC protocol 14-029D. Study volunteers provided written 
informed consent. The study was in accordance with study protocol, the International Conference 
on Harmonization of Good Clinical Practice guidelines, and applicable local regulatory 
requirements. The ClinicalTrials.gov identifier is NCT02806869.  
Materials 
USP grade phenol red (phenolsulfonphthalein) was purchased from USP (Rockville, MD, 
USA) and Avantor Performance Materials (Center Valley, PA, USA). The 0.1 mg/ml phenol red 
solution was prepared in 250 ml of water. Phenol red was dispensed by the Investigational Drug 
Service (IDS) at the University of Michigan. 
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Study Inclusion and Exclusion Criteria 
Healthy human volunteers between the ages of 18 and 55 were eligible for the study. 
Volunteers completed a physical exam and medical history screening by physician to confirm 
study eligibility. Volunteers all had normal values for vital signs, electrocardiogram, urine drug 
screen, serum pregnancy test (women only), comprehensive metabolic panel, complete blood 
count with platelet and differential, and lactate dehydrogenase.  
Volunteers were excluded if any of the following applied: inability to consent; mentally 
incapacitate; prisoners; significant clinical illness within 3 weeks prior to screening; use of 
concomitant medications including but not limited to prescription drugs, herbal and dietary 
supplements, over the counter medications and vitamins within 2 weeks prior to study; received 
an investigational drug within 60 days prior to study; history of allergy to ibuprofen or other non-
steroidal anti-inflammatory drugs (NSAIDS); pregnant or lactating females; history of severe 
allergic diseases including drug allergies; history of drug addiction or alcohol abuse within 12 
months; clinically significant abnormal lab values during screening; any other factor, condition, 
or disease including but not limited to, cardiovascular, renal, hepatic or gastrointestinal disorders 
that may, in the opinion of the investigator, jeopardize the safety of the patient or impact the 
validity of the results.  
Study Procedure 
Clinical procedures were conducted at either the Michigan Clinical Research Unit or the 
Medical Procedures Unit of the University of Michigan hospital. Volunteers were instructed to 
fast 14 hours prior and to avoid consuming water 11 hours prior to dosing. A physical exam was 
performed to ensure the health of subject prior to GI catheter intubation procedure. Volunteers 
received a topical anesthetic (1mL of 4% lidocaine before catheter insertion. Lubricating jelly 
22 
 
was applied to the GI catheter which was then orally inserted into the GI tract of the volunteer. 
Catheter placement was confirmed under abdominal fluoroscopy to ensure proper positioning in 
the GI tract. Upon placement completion, the GI catheter was taped and kept open with saline 
solution throughout the study duration.  
Volunteers were administered a single oral dose of ibuprofen (800 mg tablet) 
administered with 250 mL of phenol red. This was swallowed by the volunteer and not 
administered through catheter. GI fluid samples were collected through aspiration of available 
ports from the catheter. Prior to sample collection, contents from previous aspirations were 
collected and discarded. This discard volume ranged from 1.7mL to 3.2mL. If air bubbles were 
observed, at least 30 cc of air/fluid mixture was collected and discarded. GI sample collection 
times include 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, and 7 hours post dose. Supernatant was 
collected after sample centrifugation at 21,000 x g for 5 minutes and stored at -80⁰ C. The GI 
catheter was removed from the volunteer at 7 hours.  
HPLC analysis of Phenol Red in GI Fluid 
All samples of phenol red were analyzed with an Agilent 1200 series HPLC system 
HPLC system (Agilent Technologies, Santa Clara, CA). The HPLC system consisted of Agilent 
pumps (1100 series), an Agilent autosampler (1200 series), and an Agilent UV-Vis detector 
(1100 series) controlled by Chemstation® 32 software (version B.01.03). Samples were resolved 
in Agilent Eclipse XDB-C18 reverse-phase column (3.5 µm, 4.6 × 150 mm) equipped with a 
guard column for phenol red. The mobile phase consisted of 0.1% TFA/water (Solvent A) and 
0.1% TFA/acetonitrile (Solvent B) with the solvent B gradient changing from 0–56% at a rate of 
2%/min during a 14-minute run. Standard curves generated for phenol red were utilized for 
quantitation of integrated area under peaks. The detection wavelength was 430 nm.  
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Results 
Gastric Secretion and Emptying 
Average gastric emptying behavior was observed to be first order and net fluxes were 
attributed to either be emptying or secretion. Temporal stomach fluid content data from the MRI 
study was fitted using Matlab’s fitting toolbox. The equation for fitting is defined in Equation 11. 
The fitted equation is illustrated in Figure 5. 
 𝑉(𝑡) = (242) ∗ 𝑒i_∗1 + K__ (11) 
 
Figure 5. Best fit of the gastric emptying behavior (Equation 5) to clinical data. 
 
The initial stomach volume was based on the first observed time point (242 mL). The resulting 
fit found the coefficients for 𝑘;F and 𝑘ZF to be 1.425 mL/min and 0.0699min-1 respectively (table 
1). The R square for the goodness of fit was 0.993. This is within the range of the typical daily 
adult gastric secretion of 2-3L or 1.39 to 2.08  mL/min. (32) 
Small Intestine Transit Rates 
To determine the optimal transit rate coefficients, a compartment model was used to 
simulate the transit of drug through the small intestine based on a 199 min mean residence time 
(50% exit from small intestine to colon) determined by a previous study (38). Due to having 
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more than one transit variable to solve, a range of forward and reverse rate coefficients were 
evaluated. A 3D visualization of residual fit as a function of forward and reverse rate coefficients 
is shown in Figure 6a.  Figure 6a visualizes the natural relationship between the forward and 
reverse coefficients which minimizes the predicted transit vs. experimental measurement. The 
combination of forward and reverse rate transit coefficients with the lowest residual was chosen 
as the optimized values (0.92 min-1 forward and 0.269 min-1 reverse) (Table 1). The optimized 
transit rates were then used in the model. The resulting cumulative drug exit in Figure 6b closely 
resembles the small intestine MRT of the original CAT approach. 
 
Figure 6a. Residual evaluation of overall transit behavior for various forward and reverse rate 
coefficients relative to small intestine MRT. 6b. DFCAT MRT compared with the MRT used in 
the CAT model. 
 
Small Intestine Secretion Rate 
Assuming net absorption throughout the small intestine, the resulting term that allows for 
the variation necessary to govern total small intestine volume is duodenal secretion. Duodenal 
secretion was assumed to change over time and the values for duodenal secretion were 
determined via an optimization algorithm to determine an estimate for duodenal secretion based 
on the total volumes observed in the simulation. Values for duodenal secretion rate range from 0 
to 4.5 mL/min (table 1). The final secretion value represents the duodenal secretion necessary to 
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return the system to the basal volume observed in the beginning of the fluid MRI study. 
Secretion below the pylorus is roughly 4 liters daily (1 liter bile and 3 liter pancreatic) (33) This 
translates to roughly 2.78 mL/min which is reasonable with the values used in the model.  
Average Gastrointestinal Fluid Volume Over Time 
Model verification was conducted based on fluid MRI study data that ranged from 0 to 
120 minutes. The upper and lower small intestine were categorized by the MRI study as the 
proximal duodenum to proximal jejunum and distal jejunum to distal ileum respectively. This 
was recognized in model form as small intestine compartments 1-4 and 5-30 respectively based 
on the approximate distance for each compartment (roughly 20 cm). The observed and simulated 
stomach and small intestine physiological fluid volumes over time (excluding mucosal volume) 
are shown in Figure 7.   
 
Figure 7. Simulated volume over time in different regions of the GI tract. Upper intestine is 
designed by compartments 1-4 based on physiology with the lower by compartments 5-30. (Blue 
line represents simulated average. Red line represents experimental mean ± SEM). 
 
 
The simulation of stomach volume generally fit within the standard error of the mean 
(SEM) as the volume decreased after the initial water dose. The use of first order gastric 
emptying and zero order gastric secretion appear to capture the average transport behavior in the 
stomach. In comparison, the simulated small intestine results do not follow the experimental 
profile as well as the stomach volumes. This could be due to the use of an absorption rate 
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constant from another clinical study with a different population, mixing of water with the fluid 
layer lowering observed fluid volume, and/or large variation in regional absorption. In addition 
to these possibilities, the observation differences between simulated and experimental fluid 
volumes in the upper and lower small intestine can also be explained by the natural formation 
and transport process of fluid pockets in the GI tract. A comparison of fluid volumes used in the 
DFCAT and currently used mechanistic oral absorption models is provided as a reference in 
Table 3.  
Table 3. Comparison of fluid volumes used in mechanistic oral absorption models 
 Volume (mL)  
GI 
Compartment 
SimCyp** GastroPlus** GI-Sim** DFCAT* GI Resize 
1 53 50 47 5.6-63.9 1-4 
2 35 48 42 5.1-38.6 5-8 
3 24 175 150 4.3-24.6 9-12 
4 24 140 120 3.5-16 13-16 
5 14 109 94 2.7-10.5 17-20 
6 14 79 71 2.1-6.9 21-24 
7 14 56 50 1.6-5.6 25-28 
8 14 53  0.6-2.8 29-30 
9 13 57    
*Compartments have been resized for comparison. Compartment numbers are listed in the GI 
resize column. Values do not include mucus volume.  
**Values from Sjögren et. al (8).  
Model validation with Non-absorbable Phenol Red in the GI 
Since phenol red is a non-absorbable maker in the GI tract, the GI local concentration 
change of phenol red after oral dosing of 100 µg/ml solution is only affected by the GI fluid 
volume change and transit. Therefore, phenol red GI local concentration is used to validate the 
DFCAT model. A simulation was conducted for fluid volume and phenol red transit replicating 
the dosing scenario observed in the phenol red intubation clinical study. The average phenol red 
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concentration was used. The initial dose volume was 274 mL with an average phenol red dose of 
23.4mg (85 µg/ml). The simulated volume (excluding mucosal layer), mass, and concentration 
are shown in Figure 8. The blue line corresponds with the first compartment or duodenum.  
 
Figure 8. Simulated volume/phenol red mass/phenol red concentration over time in different 
compartments of the small intestine (each line represents a different compartment) 
 
The design validation results of comparing simulation with experimental results are 
shown in Figure 9. 
 
Figure 9. Comparison of local GI concentration samples of phenol red (red) vs Simulation (blue) 
 
 
 The predicted concentration generally falls within the average and standard error of the 
mean observed phenol red concentrations. While the behavior cannot be considered ideal in the 
proximal and mid jejunum as the simulation results in a higher concentration at the early time 
points, the study volunteers and physiology as well as stochastic variation differ between the two 
clinical studies. The closeness of the trend was considered well replicated by the simulation.  
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While the duodenum is the first compartment to peak in terms of total phenol red content, 
other compartments follow rapidly as it transports down the small intestine, and there is an 
extensive distribution of phenol red through the small intestine. Within two hours, there is 
significant phenol red distribution throughout the small intestine. On the other hand, the large 
initial quantity of fluid ingested means that initial compartments do not experience the highest 
concentration possible. This occurs in the later compartments where water absorption has 
contributed significantly to alter the fluid volume in the GI tract.  
An illustration of the DFCAT GI fluid volume, phenol red mass, and phenol red 
concentration at 30 minutes post dose is shown in Figure 10.  
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Figure 10.  DFCAT GI fluid volume, phenol red mass, and phenol red concentration at 30 
minutes post dose. 
The transit of phenol red is rapid, reaching past the middle small intestine by 30 minutes. 
On an average basis, there is fluid distribution throughout the small intestine with 10 mL in the 
duodenal compartment and just over 5mL in the last ileum compartment. After the initial dosing 
of water, the average basis fluid volumes do not change rapidly in the small intestine and as 
such, lead to an overall shape of the mass profile that is like the concentration profile over all the 
small intestine compartments.  
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Discussion 
Recent research efforts have been focused on clarifying the numerous complexities in the 
oral drug absorption process. The OrBiTo project is such an initiative dedicated to establishing 
new frameworks and tools for predictive biopharmaceutics regarding oral drug delivery (46). 
One topic of interest is the local GI fluid volumes within the gut lumen resulting from fluid 
intake, secretion, and reabsorption. This is a critical factor in the oral absorption process as the 
change of fluid volume within the gut lumen can have a significant effect on the dissolution of 
the drug and hence the concentration presented to enzymes and transporters within the enterocyte 
(3). While MRI studies have provided quantification of GI fluid volumes, the dynamic change of 
the fluid volume as well as the intermediate process of fluid absorption, secretion, and transit that 
occurs GI tract remains difficult to characterize.  
Understanding the dynamics of GI fluid transport is essential to improvements in 
predicting in vivo dissolution from mechanistic models. Measurement of GI fluid volume 
through imaging has provided valuable knowledge of GI fluid quantification. However, the data 
obtained remains as snapshots in time and does not detail the degree of absorption, secretion, and 
transit that occurs. The DFCAT model was established to mechanistically interpret the dynamic 
changes and intermediate knowledge using a methodical approach based on design verification 
and validation using phenol red concentration in the GI tract. 
Design verification was based on the GI fluid quantification via MRI. The MRI method 
(30) used to obtain the in-vivo fluid volume  (28) measured only freely mobile water with long 
transverse relaxation time, hence fluid components with restricted mobility and shorter 
transverse relaxation times (e.g. water in mucous) were not accounted for. If the mixing of fluid 
and mucus prevents the fluid from being quantified, it would explain why the total volume of 
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fluid measured was underestimated and that the simulated volume may be closer to reality. This 
could explain the significant drop when assessing the mass balance of fluid from the stomach 
into the small intestine. The quantity of mucus in the GI tract has not been well characterized and 
is not usually considered a major contributor to drug dissolution and oral drug absorption. 
However, the weight of evidence from this model suggests the mucus layer is present and its 
volume can affect local GI concentrations given the surface area of the small intestine.   
In addition, in the MRI measured fluid volume, a minimum threshold of 0.5 mL per fluid 
pocket was applied to the quantitation in (28). This was done since the contribution of very small 
pockets of fluid in the small bowel comprised only 0.5% of the total volume detected in the small 
bowel whilst their inclusion confused the display and interpretation of data. The 0.5mL is not a 
lower detection limit, but rather a single MRI image pixel of adequate brightness against the 
validated calibration (30).  Therefore, the total volume of fluid measured by MRI was likely be 
underestimated.  
Other imaging techniques such as Positron Emission Tomography (PET) have obtained 
an average volume of 313mL which is significantly larger than the MRI derived volume of 105 
mL (27, 31). However, this tends to overestimate the total volume as the marker can spread 
along the small intestine walls. This difference can be explained by the presence of a mucus 
layer and would suggest that an estimated volume of 150 mL is reasonable to describe the small 
intestine mucus layer.  Design validation of DFCAT was based on the experimentally determined 
local GI concentrations of phenol red. Despite the variation that was observed between the 
simulated and experimental fluid profiles, the simulation and experimentally observed phenol red 
concentrations in the GI tract were similar suggesting the model is representative. It is critical to 
note that there is a significant variation in the GI local phenol red concentration due to the 
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stochastic nature of the GI tract. The use of a continuous model was to simplify the approach to 
characterize average tendencies and trends. In this regard, the DFCAT model can explain the 
change in local GI fluid volumes.  
A primary assumption in the DFCAT model is that transport is defined by first order 
kinetics. First order kinetics was used in the model to define gastric emptying, transit rate in the 
small intestine, and water absorption. Of these processes, only gastric emptying and water 
absorption have been experimentally determined to be well approximated by first order kinetics 
(39-41). The transit rate in the small intestine has only noted to be faster in the proximal regions 
and slower in the more distal regions (5). The use of first order kinetics can mathematically 
approximate this behavior to a certain extent but certainly does not mimic the complete 
peristaltic effect observed in the small intestine.  
The use of verification and validation in establishing the DFCAT model also presents 
limitations. The model presently is only designed to simulate the fluid volume after intake of 
water in the fasted state. There are numerous physiochemical aspects in the GI tract such as 
conductivity, pH, and osmolality that can impact oral drug delivery (5). Changing the drink or 
simulating a fed state may result in a significantly different profile with different GI secretions. 
Each change in study conditions would require a new MRI fluid study to quantify the fluid 
model as well as a new intubation study to obtain the local GI concentrations under fed 
condition.  
The DFCAT as presented is a methodology to model GI fluid transport based on 
experimentally obtained fluid volume, which is also validated by local phenol red concentration 
in the GI tract. While the verification and validation do not include drug absorption, the 
framework can be expanded to predict drug dissolution and oral drug absorption as referenced in 
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the compartmental equations. Since local GI fluid content is critical to drug dissolution and oral 
absorption, the approach used to construct the DFCAT model can be integrated with existing 
physiologically based pharmacokinetic (PBPK) models. Along with the fundamental knowledge 
of the GI tract developed by the OrBiTo project, the integration of local GI fluid and other 
physiological considerations can integrate in vitro and in silico approaches to improve the oral 
drug development process.  
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Chapter 3 A Novel GI Fluid Transport-Based PBPK Model to Enable Prediction of 
Regional GI Drug Dissolution and Establishment of In Vitro-In Vivo Relationship 
 
 
Accurate prediction of in vivo dissolution can assure therapeutic efficacy and safety of 
oral drug products. As such, extensive effort has gone into characterizing and reproducing the 
physiochemical properties of the gastrointestinal environment as a basis for in vitro dissolution 
testing. This is well intended to support dissolution testing as a convenient surrogate test for in 
vivo biopharmaceutical performance. However, both the absolute rate and extent of dissolution in 
vivo difficult to define and the in vitro-in vivo relationships between dissolution and plasma 
profiles can be difficult to define. Therefore, it is difficult to conclude whether an in vitro 
dissolution is reflective of an oral drug product’s in vivo performance.  
Quantification of both the rate and extent of dissolution in different regions of the 
gastrointestinal (GI) tract would provide a valuable reference for designing and calibrating in 
vitro dissolution tests to better reflect in vivo biopharmaceutical performance. However, direct 
quantification of in vivo dissolution rate and extent in the human body is currently unfeasible due 
to technological limitations and as such, an indirect method such as a computational method 
must be used to estimate in vivo dissolution.  
Deconvolution methodologies such as the Wagner-Nelson and Loo-Riegelman have been 
used to estimate rate of absorption and used in support level A in vitro-in vivo correlations 
(IVIVC) (48-50). Application of deconvolution can further be applied to mechanistic models. 
For example physiologically based pharmacokinetic (PBPK) models have demonstrated potential 
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to bridge the dissolution and absorption gap and establish improved IVIVC (51). However, the 
complexity of the system requires the use of factors such as time scaling/time shifting and 
absorption time cut-offs to successfully deconvolute plasma profile (52). While the use of these 
models can predict an extent of release and a local drug concentration in various regions of the 
GI tract, the limited validation of the gastrointestinal compartments is unable to provide 
confidence in prediction.  
There have been many efforts to further clarify the GI environment and the resulting in 
vivo dissolution. GI fluid has been quantified by MRI and a dynamic model that integrates these 
results has been developed. Intubation based clinical studies have experimentally observed 
human in vivo GI concentration samples. These clinical studies provide a new reference 
perspective for the consideration and application of computational models regarding the human 
gastrointestinal environment.  
The Expanded Dynamic Fluid Compartment Absorption and Transport (EDFCAT) 
integrates the original model’s characterization of human in vivo GI fluid transport and 
expands the conceptualized compartments to include the three different drug phases of solids, 
particles, and dissolved drug (53).  The in vivo dissolution profile of an 800mg ibuprofen tablet 
was determined by deconvolution of the observed plasma profile using EDFCAT and a 
computational algorithm based on a least residual approach. Extent of regional dissolution was 
determined through a deconvolution of individual plasma profiles tailored to unique gastric 
emptying times specific to ibuprofen appearance in plasma. The distribution of simulated in vivo 
GI concentrations was used to validate against the observed in vivo GI drug concentrations from 
a clinical study.  In future applications, the use of deconvolution combined with the EDFCAT 
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can be used to estimate in vivo dissolution rate, dissolution location, dissolution profile and 
extent of dissolution. 
Material and Methods  
An expansion of the Dynamic Fluid Compartment Absorption and Transport model is 
detailed in this section to capture the essential components of drug disintegration, dissolution, 
and absorption (53). The model consists of 126 nonlinear ordinary differential equations (ODE). 
The stomach is represented by four ODEs (solid dose, drug particles, dissolved drug and fluid) 
with the small intestine represented by 120 ODEs representing a 30-compartment model. 
Systemic circulation is represented with a central body and peripheral compartment. An 
illustration of the proposed compartment model and avenues of transport is drawn in Figure 11.  
 
Figure 11. Dynamic Fluid Compartmental Absorption and Transit (DFCAT) approach with drug 
disintegration and dissolution 
Matlab 2017a was used for both the simulation of model ODEs and the prediction of rate 
coefficient parameters. A fixed step ODE solver from the Simulink Package (ODE4) was used in 
1s intervals. Visualized data graphics were rendered using Matlab’s plot packages. 
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Pharmacokinetic fitting was conducted using Phoenix 64 Build 6.3.0.395 WinNonlin version 6.3 
by Pharsight.  
 
Experimental Data 
The experimental data modeled is from an intubation based clinical study conducted at 
the University of Michigan (54). Study volunteers were fasted prior to dosing and rested for three 
hours after intubation. Each study volunteer was then administered an 800 mg immediate-release 
(IR) ibuprofen tablet (Dr. Reddy’s Laboratories Limited (Shreveport, LA; IBU™ – Ibuprofen 
Tablets, USP, 800 mg, Lot number L400603) and phenol red in water (100 µg/mL). GI samples 
were obtained from the intubation tubes at specified time points and ibuprofen was quantified by 
LC-MS/MS. Plasma samples were drawn from blood and quantified by LC-MS/MS.  The 
protocol of the clinical study and detailed information about the LC-MS/MS method are shared 
by Hens et al (55). 
Determining Thermodynamic Equilibrium Solubility of Ibuprofen in Fasted State Human 
Gastric and Intestinal Fluids 
The thermodynamic solubility of ibuprofen was determined by the shake-flask method (25 
RPM). Gastrointestinal fluids were incubated for 24 h with an excess amount of ibuprofen (Acros 
Organics, New Jersey, NY) at 37°C. The fluids that were used for measuring the thermodynamic 
solubility of ibuprofen were aspirated gastric, duodenal and jejunal fluids of three different time 
points of subject B005-F2 (56). Following the 24 h incubation, samples were centrifuged for 15 
min at 17,000 g (AccuSpin Micro 17, Fisher Scientific, Pittsburgh, PA). The supernatant was 
diluted 10-fold with methanol (Fisher Scientific, Pittsburgh, PA) and again centrifuged for 5 min 
in order to discard any proteins that could interfere with the HPLC analysis  
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Solubility samples were analyzed by HPLC-UV (Hewlett Packard series 1100 HPLC Pump 
combined with Agilent Technologies 1200 Series Autosampler). A volume of 5 µL was injected 
into the HPLC system connected to a UV-lamp that was able to detect ibuprofen at a wavelength 
of 220 nm (Agilent 1100 Series UV lamp). An isocratic run containing 70% acetonitrile (VWR 
International, West Chester, PA) and 30% purified water (both containing 0.1% trifluoroacetic 
acid (TFA; Fisher Scientific, Pittsburgh, PA)) was used to detect ibuprofen at a retention time of 
2.9 min using a reversed-phase C-18 column (Eclipse Plus C18, 4.6 x 150 mm, 5.5 µm, Agilent 
Technologies) and a 1 mL/min flow rate. The calibration curve was made in methanol based on a 
stock solution of ibuprofen in methanol (1 mM). Linearity was observed between 10.32 µg/mL 
and 0.32 µg/mL. The observed peaks were integrated using ChemStation software (Agilent 
Technologies). The developed analytical method met the FDA requirements for bioanalytical 
method validation.  
Determining Pharmacokinetic Parameters for Deconvolution 
Deconvolution of plasma profile requires a mathematical conceptualization for the 
system of interest. A two-compartment model is used to characterize the bio-distribution of 
ibuprofen in the body with one compartment representing a central and the other as the 
peripheral compartment. By fitting the plasma profile of intravenous infusion of 800mg dose of 
ibuprofen to a two-compartment based pharmacokinetic model, pharmacokinetic parameters 
(𝑘TP,	𝑘PT,	𝑘) can be obtained (57).  The drug absorption rate constant (𝑘&) was obtained by 
utilizing the pharmacokinetic parameters obtained and fitting the solution dosing based on the 
clinically observed plasma profile after a 420mg solution dose of ibuprofen using the DFCAT 
model (58, 59).  
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Model verification criteria was based on the experimentally observed ibuprofen plasma 
concentration profile. If the algorithm could determine the appropriate dissolution rate, the 
simulated plasma profile would align closely with experimental observations. Model validation 
criteria was based on the experimentally observed ibuprofen GI drug concentration profile. The 
mechanistic deconvolution of ibuprofen dissolution from plasma profile results in a simulated 
continuous model of fluid, dissolved drug, drug particles, and solid drug in the GI tract. If the 
resulting local GI concentration profiles are reasonable, the simulated GI concentration profile 
would align closely with experimental observations.  
Determining in vivo Dissolution Rate Using Deconvolution Based Algorithm 
Dissolution was assumed to be the limitation factor in the absorption of ibuprofen from 
the GI tract. The dissolution profile was obtained with an algorithm (Figure 12) that determine 
the necessary dissolution rate coefficient based on the least residual difference between 
simulated and experimentally observed plasma concentrations. Linear interpolation was used to 
determine a continuous plasma profile between experimental time points as Area-Under-the-
Curve (AUC) is traditionally determined by trapezoidal rule.  
 
Figure 12. Residual based mechanistic deconvolution algorithm based on the DFCAT model. 
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Determining Individual Variability Based on Inflect in Plasma Profile 
Individually observed plasma profiles in the clinical study were typically observed to be 
low until a certain time had been reached (tlag). This time varied between individuals with an 
average of 82 minutes. Upon reaching this time, the observed plasma profile increased at a 
significant rate. Based on ibuprofen’s classification as a BCS Class IIa drug, it is reasonable to 
associate this behavior with gastric emptying. This is supported by the physiological understanding 
where motility is linked with extra pancreatic secretions to neutralize incoming stomach acid (60). 
To best determine the rate and extent of dissolution in vivo that is representative of actual rather 
than averaged behavior, each observed plasma profile was assigned a tlag based on the observed 
inflection time. Estimation of regional dissolution was dependent on a point of inflection (second 
derivative) or a notable visual increase plasma profile which was assumed to reflect the event of a 
stochastic gastric emptying event. Individual gastric emptying rates were adjusted to match the 
limited absorption and a corresponding differential equation term was developed to approximate 
complete gastric emptying. Individual dissolution profiles were then deconvoluted from each 
fasted volunteer’s plasma profile. All pharmacokinetic parameters were assumed to remain 
identical with volume of distribution being the primary variable that differentiates individuals.  
Model Verification and Validation 
To evaluate model cogency, a series of model verification and validation checks 
conducted with figure xx describing the overall approach. The dissolution profile over time is 
determined by deconvoluting the plasma profile using the EDFCAT model. A model verification 
check is conducted by comparing the resulting simulated plasma profile with the experimentally 
observed plasma profile. As the observed plasma profile is not a continuous measurement but 
rather distinct temporal observations, an interpolation method can be used to draw continuous 
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linear lines from one time point to the next. As the mechanistic model also simulates the distinct 
local GI concentrations, a validation check can be conducted based on comparing the simulated 
GI concentration with the experimentally observed GI concentrations. This was based on the 
duodenum being compartment 1, jejunum being compartments 2-13 and the ileum being the 
remaining 14-30 compartments. The compartment assignments were analogous to the physiology 
of the GI tract based on 21cm per compartment assignments. 
 
Figure 13. Overview of Conducted Verification and Validation in Developing a Prediction of in 
vivo Dissolution. 
Equations 
Disintegration of Solid Dose into Particles 
The disintegration of solid dose into drug particles was assumed to have a minimal effect 
on oral absorption of ibuprofen based on the immediate release formulation used. The solid dose 
was assumed to disintegrate and rapidly and completely by reference time 𝑇=. Based on this 
assumption, disintegration can be represented by a hyperbolic tangent function (Equation 12).  
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 TP ∗ tanh Siyx + TPU ∗ 0.1 ∗ 𝑆2) (12) 
Where 𝑇= is the referenced time of complete disintegration and 𝑆2 is the amount of dose in the 
solid dosage form.   
Forward Transit of Solid Dose 
Like existing models, the transit of solid dose was modeled to occur based on set points 
in time. To provide a continuous function for the solving of ordinary differential equations, a 
hyperbolic tangent was used to define the timing of the transfer of solid dose from one 
compartment to the next (Equation 13).  
 TP ∗ tanh SiXyzLKJX + TPU ∗ 0.1 ∗ 𝑆2) (13) 
Where 𝑇1=&2;"1 is the reference time for the transit of solid from the and 𝑆2 is the amount of drug 
as in solid form.  
Transit of Particles in the Gastrointestinal Tract 
Transport of drug particles was characterized by disintegration from solid, dissolution 
into solution, and transit through the GI tract. Transit of particles is assumed to be completely 
analogous to transit of dissolved drug and is represented by equation 14.  
  𝑑𝑃transit = 𝑘,\|] ∗ 𝑃2 ∗ GLGtjGL (14) 
Where 𝑘,\|] is the rate coefficient for forward and reverse transit as determined in the 
DFCAT model, 𝑃2 is the amount of drug in particle form in compartment n, 𝑉2 is the volume of 
the compartment n, and 𝑉:  is the mucus volume. Mucus volume was assumed to not affect the 
general transport dynamics of drug particles and as such, this equation conceptualizes the drug 
particles instantaneously equilibrium distribution between fluid and mucus volume. 
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Dissolution of Particles into Solution 
As disintegration was assumed to be completed rapidly, dissolution from particle into 
solution becomes the limitation factor to drug absorption. The dissolution of drug particles into 
solution was represented by a modified Nernst-Brunner equation (Equation 15) (25) . 
 BLB1 = 𝑘B";;(𝑡)(𝐶F − 𝐶2) (15) 
Where 𝑘B";;  is the first order dissolution rate coefficient, 𝐶F is the maximum in vivo solubility 
determined experimentally, and 𝐶2 is the concentration of the compartment. The use of a 
temporal first order coefficient 𝑘B";;(𝑡) was used to represent temporal changes in dissolution 
and as a modifier of dissolution rate for deconvolution. This approach has been previously 
explored in Margolskee et al (61). In comparison with the Nernst-Brunner dissolution equation, 
this temporal coefficient serves as an approximation of the diffusion coefficient, surface area, 
and thickness of the boundary layer.  
Continuous Gastric Emptying Term Based on tlag 
To simulate gastric emptying based on a tlag, a double hyperbolic tangent equation was 
applied to provide an approximation of a binary situation (Equation 16). In the provided equation, 
if: 
t < tlag: 
BLB1 = 0 
 tlag < t < tlag+10: 
BLB1 = 1 
t > tlag+10: 
BLB1 = 0 
A total possible gastric emptying time of 10 minutes was assumed based on phase III 
migrating motility complex.  
 BLB1 = STP ∗ tanh SiTix.T U − TP ∗ tanh Six.T UU ∗ 𝑚2 (16) 
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Results 
Determining 2-Compartment Pharmacokinetic Parameters 
Pharmacokinetic parameters were determined based on a 2-compartment infusion using 
Winnonlin. The determined pharmacokinetic parameters are as follows: 𝑘T is 0.013min-1, 𝑘TP is 
0.047min-1, 𝑘PT	0.069min-1, and Vd=5.32L. A graph of the fitted compartment model is shown in 
Figure 14a. The adoption of the 2 compartment pharmacokinetic parameters used in the DFCAT 
approach to model the resulting plasma profile. A range of absorption terms were simulated with 
the lowest residual difference between simulation and experimental plasma profile determining 
the absorption rate. The absorption rate coefficient of ibuprofen was determined to be 3 min-1. A 
graph of the comparison between simulation and experimental solution dosing is shown in 
Figure 14b.  
 
  
Figure 14. (a,left) Fitted two compartment pharmacokinetic model based on 800mg IV infusion. 
(b,right) Fitting the absorption rate value based on 420mg solution dosing IV determined 
pharmacokinetic parameters in the DFCAT model. 
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Quantifying Solubility in Human Gastrointestinal Fluids 
The in vivo solubility of ibuprofen was determined to be low at pH <3.5 at roughly 55 
µg/mL. The solubility increases at higher pH’s reaching a solubility of 1990 µg/mL at pH 6.2. 
An illustration of thermodynamic solubility of ibuprofen over a range of pH values based on 
human intestinal fluid samples is shown in Figure 15. A study conducted by Heikkila et al. also 
observed an ibuprofen thermodynamic solubility to be 1990 µg/mL in fasted human intestinal 
fluid (62).  
 
Figure 15. Experimentally determined thermodynamic solubility profile of ibuprofen based on 
human gastrointestinal fluids 
 
Predicted Dissolution and Model Verification with Average Plasma Concentration Profile 
The deconvolution algorithm was set to ±0.5µg/mL tolerance check at every six minutes. 
Based on this criterion, the algorithm could successfully determine a dissolution rate coefficient 
to simulate a plasma concentration profile similar to the experimental profile (Figure 16). Slight 
variation as evident around the 200-minute time point is minor and could be reduced by 
tightening the min-max of the allowed residual bounds.   
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Figure 16. Comparison of simulated vs experimental ibuprofen plasma concentration profile 
based on mechanistic deconvolution using the DFCAT model. 
 
Predicted Dissolution and Model Verification of Individual Plasma Concentration Profile  
The deconvolution algorithm was applied to each individual plasma profile identical to 
the approach used for the average plasma profile. Based on this criterion, the algorithm could 
successfully determine a dissolution rate coefficient that was necessary to simulate the plasma 
concentration profiles (Figure 17).  Table 4 references each individually estimated tlag and the 
amount that was determined to have dissolved by the estimated tlag.  
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Table 4. Estimated Dissolution Between Upper and Lower Regions of the Small Intestine 
ID TLAG PRE-TLAG 
DISSOLUTION 
(MG) 
1 60 16.6 
2 150 42.4 
3 150 193 
4 60 147 
5 60 45.9 
6 90 83.2 
7 90 26.4 
8 12 0 
9 90 42.6 
10 150 104.6 
11 180 90.8 
12 60 65.5 
13 12 0 
14 60 21 
 
  
Figure 17. (left) Deconvolution algorithm fitting based on individual plasma profiles. (right) 
Deconvolution profiles based on individual plasma profiles 
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Predicted Rate and Extent of in vivo GI Dissolution 
The mechanistic nature of the EDFCAT model resulted in the following dissolution 
profiles when the temporal dissolution rate coefficient was obtained (Figure 18). The stomach 
had a small amount of total dissolution (<4%).  
 
Figure 18. (left) Deconvolution algorithm fitting based on individual plasma profiles. (right) 
Deconvolution profiles based on individual plasma profiles 
 
Based on the assumption that complete emptying of the gastric contents occurs at the tlag 
timepoint, the amount of dissolution in the stomach region clearly ceases as there is no remaining 
undissolved content in the stomach. Dissolution behavior in the duodenum is similarly defined 
by the tlag time where a significant increase in the amount dissolved occurs. In most individuals, 
it was predicted to be a sharp increase in dissolution which ceased due to transit away from the 
duodenal region.  This varied significantly between individuals ranging from around 1 to 18 
percent of the total 800mg ibuprofen dissolving. The jejunum was predicted to be the largest site 
of dissolution where roughly 40 to 82% of the drug dissolved was predicted to dissolve. 
Analogous to the stomach and duodenal regions, dissolution in the jejunum is reflected by the 
tlag time. Individual comparisons between the different individuals found a similarity amongst 
the different dissolution profiles regarding the slope. It is likely that the rate of dissolution in vivo 
is similar amongst many individuals and is reflected by the gastric emptying event.  Based on the 
assumption that ibuprofen has nearly complete bioavailability, the ileum was found to contribute 
49 
 
varying degrees to the extent of ibuprofen dissolution. In absolute terms, this ranged from 10 to 
52% of the ibuprofen’s overall 800mg active pharmaceutical ingredient. The two highest percent 
dissolution in the ileum (35 and 52%) corresponded with the two individuals who had the 
shortest tmax in the observed plasma profile.  
Model Validation Based on Observed GI Concentration Profile 
The deconvoluted model simulation results in an in vivo GI profile similar in magnitude 
to the experimental profiles (Figure 19). Geometric mean and 90% geometric confidence 
intervals were used to observe the overall tendency of the GI concentrations due to the large 
observed variations in the GI. Previous studies hypothesize that this large variation can be 
explained by the lack of homogeneity in the local GI region (63). Large experimental 
concentrations variations could also be related to local GI solubility differences from GI 
secretions such as bile. Additional differences in GI concentration between simulation and 
experimental were expected as the fluid, pharmacokinetic, and GI sampling were all separate 
clinical studies. The model was evaluated on whether the general trend of observed GI 
concentration could be reproduced using deconvolution to determine in vivo dissolution and as 
such, appear as a realistic model. 
 
Figure 19. Comparison of simulated vs experimental ibuprofen GI concentration profile based on 
mechanistic deconvolution using the DFCAT model. 
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Average Predicted in vivo Dissolution Profile 
The resulting simulation based on the predicted in vivo dissolution rate and the use a 
compartmental approach provides a quantifiable amount of drug released in different regions of 
the GI tract. The average and 90% confidence interval of the individual predictions were 
calculated and are presented in Figure 20.  
 
Figure 20. Predicted in vivo percent dissolved and mass dissolved of ibuprofen over time. 
 
On average, stomach was calculated to contribute minimally to the overall dissolution of 
ibuprofen (2%). This is consistent with expectations that there would be limited dissolution in 
the stomach due to pH . The duodenal environment was calculated to contribute more than 
double the stomachs with a total of 6.3% dissolving. This is also consistent with expectations 
that dissolution is increased due to the higher pH but overall dissolution is limited as due to the 
small residence time of GI content in the duodenum. The jejunum was calculated to be the 
primary site of dissolution with a total of 63% of ibuprofen dissolving in this region over a 210-
minute period on average. This long dissolution time frame likely reflects the significant 
variability regarding the lag time for gastric emptying. The dissolution in the ileum (25%) was 
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calculated to begin after a lag time that likely reflects a combination of both gastric emptying and 
transit times.  
Discussion 
Physiologically based in silico models have often combined in vitro dissolution and 
absorption experiments with in vivo physiological parameters to create a dynamic representation 
of the in vivo oral absorption process (61). Because the in vivo GI environment differs 
significantly from current in vitro models, there is a high possibility for a poor estimation of 
physiological performance such as in vivo drug solubility. A phosphate buffer (pH 1.2, 4.5, 6.8, 
7.2) prepared accordingly to USP 30 determine ibuprofen  solubility to be 2.1, 5.1, 5.57, and 5.86 
µg/mL respectively (64). This contrasts significantly with the thermodynamic solubility 
experiment conducted based on fluids obtained from the human gastrointestinal tract. In this 
study, the solubility was observed to be 55, 58, 535, and 1990 µg/mL with a corresponding pH of 
1.5, 3.7, 4.6, and 6.2 respectively. This is an order of magnitude difference in solubility with 26 
times the solubility at low pH levels and 357 times at higher pH. As many implementations of 
the dissolution equation utilize a solubility term, it is critical to ensure that the solubility used is 
representative of the true in vivo solubility of a drug compound.  
By applying a deconvolution method to a mechanistic system, the model is also 
simultaneously able to solve for the total dissolution profile. Because many aspects of the model 
design such as fluid transport and plasma for deconvolution are from mean values or central 
tendencies, the solved total dissolution profile is representative of an average basis. This suggests 
that dissolution profile averaged across many individuals in the clinical study is likely not 
representative of exact in vivo performance but rather an approximation of overall expectations 
with roughly 70% dissolved around 200 minutes and 90% around 350 minutes.  
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The simulation predicted an average basis of dissolution for each region with a total of 
16, 37, 508, 188 mg dissolving in the stomach, duodenum, jejunum, and ileum respectively. The 
predictions regarding stomach and duodenum align with expectations regarding regional drug 
dissolution. While the gastric environment was not anticipated to be a major site of dissolution 
due to the limited solubility at low pH, the model calculated a total dissolution of 16 mg on 
average. The duodenum was also not expected to be a significant contributing site due to its 
proximity to the stomach, the lower pH, and the limited residence time for transit. As such, the 
observed 37mg total dissolution on average is reasonable when compared with the stomach. In 
comparison, over half of the ibuprofen oral drug product was calculated to dissolve in the 
jejunum with the remainder dissolving in the ileum. This is consistent with the observation that 
bioavailability of all ibuprofen formulations (100-800mg) are high.  
When examining individual dissolution profiles, mechanisms such as the secretomotor 
complex where gastric emptying is accompanied by extra pancreatic secretions is evident (60). In 
the individually based simulations conducted, a significant increase in plasma profile was 
conceptualized using a gastric emptying lag time. The resulting simulation determined high rate 
of dissolution for ibuprofen upon conclusion of the gastric emptying lag time.  In a few 
individuals where sufficient time had elapse, a second gastric emptying event was observed 
followed by a period of increased dissolution/increase in plasma profile. Given the small increase 
and the complexity in modeling a second gastric emptying event based on the method used, the 
modeled application was restricted to a singular gastric emptying event. In general, fluid 
transport was found to becomes less variable after 30 minutes. As such, the use of individually 
based deconvolution can be a reasonable estimate of in vivo dissolution performance. This is 
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further supported by approximately parallel slopes of the in vivo dissolution profile across 
multiple individuals.  
In conclusion, the applicability of the approach developed to predict in vivo dissolution 
should be considered based on a weight-of-evidence approach and based on physiochemical 
interactions with drug properties. With the use of validation to evaluate the simulated in vivo 
concentration profiles, the model is a potentially strong approximation of in vivo behavior. With 
future studies and methods providing additional data such as the GI concentrations used in this 
model, additional improvements in both in vitro study considerations and the in silico oral 
absorption models can be used to guide further research and experimental design.  
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Chapter 4 Direct Measurement of Three Mesalamine Formulations in the Human 
Gastrointestinal Tract to Evaluate In Vivo Solubility, Absorption, and Transit2 
 
 
Inflammatory Bowel Disease (IBD) such as Ulcerative Colitis (UC) and Crohn’s disease 
affects approximately 1.6 million Americans with as many as 70,000 new cases diagnosed each 
year (65). Mesalamine (mesalazine) is commonly used to treat mild to moderate UC by 
presenting drug locally in the gastrointestinal (GI) tract at the site of inflamed mucosa (66, 67). 
To achieve high local concentration and minimize absorption in the GI tract, mesalamine oral 
drug products are designed with modified-release (MR) technology to delay drug release and 
delivery in GI tract to maximize local therapeutic effect and limit systemic exposure (68, 69).  
Currently approved mesalamine formulations in the U.S. for the treatment of UC fall into 
three major design strategies: delayed release (Pentasa), pH-dependent release granules (Apriso), 
and multi-matrix release (Lialda). Pentasa consists of microspheres encapsulated with an 
ethylcellulose semi-permeable membrane which allows for time and moisture dependent release  
(70). This allows for the formulation to distribute gradually throughout the GI tract (71). The 
Apriso capsule contains Eudragit L resin on each granule which is a pH sensitive polymer that 
disintegrates at pH greater than 6 (72). The polymer matrix for each granule swells to release 
                                               
2 Reprinted (adapted) with permission from Alex Yu, Jason R. Baker, Ann F. Fioritto, Ying Wang, Ruijuan Luo, 
Siwei Li, Bo Wen, Michael Bly, Yasuhiro Tsume, Mark J. Koenigsknecht, Xinyuan Zhang, Robert Lionberger, 
Gordon L. Amidon, William L. Hasler, and Duxin Sun. Mol. Pharmaceutics, 2017, 14 (2), pp 345–358. DOI: 
10.1021/acs.molpharmaceut.6b00641. Copyright (2017) American Chemical Society 
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mesalamine. Lialda contains a more stringent Eudragit S resin which disintegrates at pH >7 and 
is made in a Multi-Matrix System (MMX) which contains additional lipophilic and hydrophilic 
matrices (73). These formulations are expected to have different GI regional-dependent release, 
leading to different clinical pharmacokinetics and efficacy. 
Clinical studies have shown that different mesalamine formulations have a large degree 
of inter-individual pharmacokinetic variability [Cmax, Tmax, Area Under the Curve (AUC), and 
fecal excretion] for both healthy subjects as well as patients with active and inactive UC (74, 75). 
When Pentasa (1g), Apriso (1.5g), and Lialda (1.2g) were dosed in colitis patients in three 
separate clinical studies, plasma exposure varied with AUC0-n of 4.4±1.8, 11±5, and 9±5 µgh/mL 
and a Cmax of 0.99±0.53, 2.1±1.1, and 0.86±0.64 µg/mL respectively (76-78). The large variation 
in AUC is accompanied by an equally large variation in Tmax; Pentasa (3.5±1.8h), Apriso (2-
16h), and Lialda (4-32h). A further complication of the variable pharmacokinetic properties 
between different formulations is that the various studies use a different dose regimen (ie. 4x 
250mg vs. 2x 500mg Pentasa) which further confounds comparability of pharmacokinetic 
results.    
While efficacy has been proven in induction and maintenance of remission in patients 
with UC (79, 80), comparisons between different clinical studies have been difficult due to each 
study utilizing its own criteria in evaluating mesalamine efficacy. For example, one study 
concluded Asacol (2.4g/day) had 49% of patients improving after 5 weeks of treatment based on 
physician global assessment versus 23% placebo (81). Another study concluded Asacol 
(2.4g/day) achieved a 33.7% clinical remission rate versus 22.1% placebo in colitis patients after 
8 weeks (82). Comparing these two studies, the treatment endpoint varied and the assessment of 
colitis severity likely varied between physicians. The global assessments are based on the 
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severity of the condition by a physician with the disease activity accessed as quiescent, mild, 
moderate or severe.  There has been a lack of formulation comparison studies. A clinical study 
involving a 2g daily dosing of Pentasa concluded 29% of patients achieved remission by 
physician global assessment compared with 12% from placebo after 8 weeks (83).  Lialda 
(2.4g/day) and Asacol (2.4g/day) achieved a 41.7% and 33.7% clinical remission rate, 
respectively, versus 22.1% placebo in colitis patients after 8 weeks in a comparison study (82). 
This difference in baseline placebo remission may be a result of a variety of study differences 
such as, but not limited, to baseline level of the disease and endpoints assessed.  
Meta-analysis of literature data have generally found oral 5-ASA products  to be more 
effective than placebo in induction and maintenance of remission of UC with similar remission 
rates (84). A comparison study between pH-dependent release and time-release mesalamine 
formulations reported no difference in induction of remission (85). While cross study analysis 
can be conducted, head-to-head comparison is not conclusive to determine whether one 
formulation is superior in clinical efficacy to another as study methods differ(66, 82, 86-90). 
Further, it is unclear whether different mesalamine formulations will have different efficacies in 
IBD patient subgroups. Furthermore, it is not known if mesalamine in systemic circulation can 
be used as an indicator of efficacy or even formulation GI release behavior.  While a direct 
comparison of mesalamine concentration in the GI between different formulations would be 
ideal, there are no reported results regarding the GI concentration of mesalamine from each 
formulation in the GI tract.  
The lack of critical results simultaneously measuring local drug release and drug 
dissolution in the GI tract and plasma levels, creates uncertainty in determining whether these 
locally-acting mesalamine formulations have clinically relevant differences and whether these 
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drug products are clinically interchangeable. It is thus difficult to assess the bioequivalence of 
generic drug products for locally acting mesalamine products.  Current bioequivalence (BE) 
standards oral drug products for a majority of systemic delivery are well-established and well-
validated using plasma Cmax and AUC. However, whether the use of plasma pharmacokinetics 
can be used to ensure BE for locally-acting gastrointestinal drugs has been debated over the past 
many years (91-93). BE for locally acting GI drug products would ideally correlate with the 
drug’s local GI availability. 
The aim of this study was to conduct a human GI intubation clinical study to directly 
measure mesalamine levels (release and dissolution) for three different formulations (Pentasa, 
Apriso, and Lialda) in different regions of the human GI tract (stomach, duodenum, jejunum, 
ileum); and to estimate mesalamine content in colon by measuring mesalamine and metabolite 
excretion in feces; and finally to investigate the relationship between plasma concentration-time 
profiles and drug concentration-time profiles in the GI tract. These results will provide a direct 
scientific basis for using pharmacokinetic plasma endpoints to evaluate the bioequivalence of 
locally acting drug products in the GI tract where local in vivo dissolution directly impacts the 
efficacy of the drug product.  
The aim of this study was to conduct a human GI intubation clinical study to directly 
measure mesalamine levels for three different formulations (Pentasa, Apriso, and Lialda) in 
different regions of the human GI tract (stomach, duodenum, jejunum, and ileum) to evaluate in 
vivo solubility, the dissolution of these mesalamine products based on traditional deconvolution, 
and the contribution of GI transit. These results will provide a direct scientific basis to improve 
mechanistic oral absorption models by integrating in vivo drug solubility, prediction of 
absorption rate, and the contribution of GI transit variability.  
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Materials and Methods 
Materials  
Pentasa (500 mg capsule, Shire US Inc., Wayne, PA), Apriso (375 mg capsule, Salix 
Pharmaceuticals, Inc., Raleigh, NC) Lialda (1200 mg tablet, Shire US Inc., Wayne, PA) were 
purchased through the Investigational Drug Service (IDS) of the Department of Pharmacy at the 
University of Michigan Health System. The solution of mesalamine (100 mg/125 mL) was 
prepared by dissolving the crushed mesalamine tablet from Delzicol (400 mg capsule, Warner 
Chilcott (US), LLC, Rockaway, NJ) in water. The intubation tube was custom designed by the 
study team and manufactured by Arndorfer Inc., Greendale, WI.  
Clinical Study 
Male and female subjects between the ages of 18 and 55 years were eligible for inclusion 
into the study. The body mass index (BMI) requirement for healthy subjects was BMI 18.5 to 35. 
Exclusion criteria included adults unable to consent for themselves, prisoners, clinical illness 
within 3 weeks, concomitant medication use, history of gastrointestinal surgery, allergy to non-
steroidal anti-inflammatory drugs (NSAIDS) or the mesalamine formulations (Pentasa, Apriso, 
Lialda, Delzicol), drug allergies, history of drug addiction or alcohol abuse within 12 months, 
pregnant or lactating females, surgery within the past 3 months, investigational drug use within 
60 days, or any clinically significant abnormal lab values during screening.  All subjects were in 
good health as determined by medical history, physical examination, vital signs, 
electrocardiography, and clinical laboratory tests. The study protocol was approved by the 
institutional review boards (IRB) at the University of Michigan (IRBMED, HUM00053912) and 
the Food and Drug Administration IRB (also known as the Research Involving Human Subjects 
Committee or RIHSC, #11-072D). All subjects provided written informed consent to participate. 
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The study was carried out accordance with the protocol, International Conference on 
Harmonization Good Clinical Practice guidelines, and applicable local regulatory requirements. 
Study Design 
The study consisted of a Crossover Arm (modified release formulations) followed by a 
Single-Arm Treatment (oral mesalamine solution). Each participating subject completed at least 
one MR dosing with one of the three formulations assigned at random using block 
randomization. Upon completion of the first MR dosing, subjects could elect to participate with 
the remaining formulations chosen at random until all three formulations were administered. 
After successful completion of any MR dosing, study subjects could elect to complete the oral 
solution dosing arm.  In the MR dosing, subjects received a dose of mesalamine (IIA: Pentasa 
(2x 500mg), IIB: Apriso (3x 375mg), IIC: Lialda (1x 1200mg)). Blood, intestinal fluid, and feces 
were collected for the MR treatment. In the oral solution dosing, study subjects received a single 
100mg oral dose of mesalamine (i.e. crushed and dissolved mesalamine tablet given in water). 
After study drug administration, only blood, and feces were collected for the oral dosing group. 
Both mesalamine and its metabolite were quantified for each sample. pH values were also 
measured for intestinal fluid samples. A minimum of 10 days was used as the washout period 
between the studies. 
Crossover Arm (MR dosing) Study Procedure  
 
All clinical procedures were performed at the University of Michigan Hospital in the 
Michigan Clinical Research Unit (MCRU). The study subject was required fast for 4 hours prior 
to arrival at MCRU, the evening before study drug administration.  A physical exam was 
performed by the study physician prior to GI tube insertion. To prevent gag reflex, study subjects 
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were administered a topical anesthetic (1mL of 4% lidocaine) before the tube insertion. The tube 
was lubricated with 2% lidocaine jelly or MediChoiceÒ medical grade lubricating jelly.  Then 
the tube was inserted orally into the GI tract.   
Prior to inserting the GI tube, 5 mL of tap water was introduced in the subject’s mouth. 
Next, the GI tube was placed on the subject’s tongue and slowly advanced toward the subject’s 
epiglottis. The subject was asked to swallow the water as the GI tube advanced beyond the upper 
esophageal sphincter. The subject performed dry swallows as the GI tube progressed toward the 
lower esophageal sphincter and intubated into the stomach.  Subjects were instructed to execute 
reverberation sounds and coughs in combination with varying radiological positioning as the GI 
tube moved forward through the pylorus bypassing the Ligament of Treitz. Using gravity and 
Trendelenburg positioning, augmented by abdominal pressure, the GI tube was traversed through 
the small bowel anatomical regions. Finally, the balloon located at the distal end of the GI tube 
was inserted with 7-10mL of sterile water. The GI tube was taped loosely to the subject’s chin 
using medical tape. The subject was encouraged to walk periodically around the medical 
procedures unit to allow antrum and small bowel peristalsis to migrate the GI tube further into 
the small bowel.  Following a one-hour time mark, the subject underwent fluoroscopic imaging 
to verify final placement of the GI tube.  The 7-10mL of sterile water was removed from the 
balloon and the GI tube was securely taped to the subject’s chin using medical tape. 
Abdominal fluoroscopy was conducted to ensure the GI tube was correctly placed.  
Fluoroscopy was performed by a radiology technologist.  The radiation exposure time was 
limited to a maximum of 1.5 minutes for each Crossover Arm (the MR dosing arm) 
procedure by the use of the fluoroscopy machine in a pulse mode.  The x-ray radiation was 
only delivered when a picture was taken. Since the fluoroscopy was not constant, this 
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limited the participant’s radiation exposure.  The study team monitored the total fluoroscopy 
time during each GI tube insertion procedure to ensure the maximum exposure time was not 
exceeded. 
Study subjects were given a light liquid snack and then requested to fast overnight and 
until 7 hours post drug administration. Prior to dosing, an intravenous catheter was placed in the 
forearm vein of the subject and the GI tube placement was confirmed with fluoroscopy. Subjects 
were asked to empty their bladder, if possible, prior to study drug administration.  At 
approximately 8:00 AM, the study subject ingested one of the three MR formulations of 
mesalamine accompanied by 240 mL of water.   
Blood samples (5 mL each) were obtained at 0, 0.5, 1, 2, 3, 4, 6, 7, 8, 10, 12, 24, 48, and 
72 hours following dosing. For Lialda dosing, an additional 96 hour blood sample was collected. 
Plasma was separated from blood samples and stored at -80oC until processing. The subject was 
also provided a container for collecting feces. Collection occurred between 0-12, 12-24, 24-48, 
and 48-72 hours following dosing. For Lialda dosing, an additional 72-96 hour feces sample was 
collected. Feces samples were refrigerated until processing. Intestinal fluid samples were 
aspirated from the multi-luminal GI tube to obtain samples from the stomach, duodenum, and 
jejunum at 0, 1, 2, 3, 4, 5, 6, 7 hours following dosing. Approximately 0.5 mL of GI fluid was 
collected from each location of the GI tract at each time point. The pH of the GI fluid was 
measured ex vivo using a pH meter with a micro pH electrode (Thermo Scientific). The GI fluid 
samples were processed and stored at -80oC until analysis.  The supernatant was used for 
analysis.  
At 7 hours post-dose, the GI tube was removed and the subject was served a standardized 
snack. At 10 hours post-dose, the subject was served a standardized meal. The subject remained 
62 
 
in the medical unit to facilitate blood and fecal collection until 12 hours post-dose. The subject 
was then discharged and asked to return for blood sample collection at 24, 48, and 72 hours post 
dose (as well as at 96 hours post-dose if Lialda is dosed). All samples were then transferred, 
prepared, and analyzed by the Pharmacokinetics Core at the University of Michigan College of 
Pharmacy.  
Single-Arm (oral solution dosing) Study Procedure 
A mesalamine solution was prepared by the pharmacist.  A 400 mg Delzicol capsule was opened 
and the tablet inside the capsule was removed.  The mesalamine tablet was crushed using a 
mortar and pestle.  Then 500mL of water was added to the crushed tablet and stirred in a beaker 
for 30 minutes. Next 125mL was removed from the agitated solution for administration to the 
study subject.  The study subject was instructed to fast from 10:00 PM to 8:00 AM. Upon arrival 
at MCRU, an intravenous catheter was placed in the forearm vein of the subject. The subject was 
administered the 100 mg dose of mesalamine in 125mL water followed by 120mL of water 
chase. Blood samples (5mL each) were obtained at 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 
hours post-dose. Plasma was separated from blood samples and stored at -80oC until processing. 
The subject received a standardized snack at 4 hours post-dose and a standardized meal at 10 
hours post-dose. The subject was discharged at 12 hours and asked to return to the medical unit 
at 24 hours to collect the last time point. All samples were then transferred, prepared, and 
analyzed by the Pharmacokinetics Core at the University of Michigan College of Pharmacy. 
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LC-MS/MS Analysis of Mesalamine and its Major Metabolite in GI Fluid, Plasma, and 
Feces 
Human plasma, GI fluid, and feces samples of mesalamine (5-ASA) and its metabolite 
(Ac-5-ASA) were analyzed by a validated LC-MS/MS assay under FDA validation guidelines. 
For feces samples, feces were assumed to have a density of 1g/mL. The total content of 5-ASA 
and Ac-5-ASA collected was estimated with the following equation: 𝑀5-ASA = 𝐶;&> ∗ (𝑉1H&2< + 𝑀;/Density) 
For plasma samples, 5-ASA and Ac-5-ASA were directly extracted by protein 
precipitation method. Briefly, 100µL of plasma samples were precipitated by addition of 400µL 
of acetonitrile containing the internal standard (4-ASA). After thorough mixing, the samples 
were centrifuged for 7 min at 15000g under freezing condition. Then a 400µL aliquot of the 
supernatant was diluted with 600µL of 0.1% formic acid water in a new polypropylene tube and 
transferred into the autosampler. For GI fluid and feces samples, 10-fold dilution was obtained 
by mixing 10µL of the raw samples with 90µL of drug-free plasma, respectively.  Once the GI 
fluid and feces samples were well-dispersed in plasma, the same sample preparation steps used 
in plasma preparation were carried out. 
The quantitative LC-MS/MS analysis was conducted using a Shimadzu HPLC system 
coupled to an API 5500 mass spectrometer (Applied Biosystems, MDS Sciex, Toronto, Canada) 
equipped with an API electrospray ionization (ESI) source. Chromatography of 5-ASA, Ac-5-
ASA and internal standard (4-ASA) was performed on a reversed-phase column (15 cm x 4.6 
mm I.D., 3.5 µm, XBridge C18, Waters), eluted with a gradient solvent system consisting of 
0.1% formic acid and acetonitrile, and monitored by mass spectrometer with a MRM method as 
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follows: the transition of m/z 152.0 to the production ion m/z 108.0 for both 5-ASA and 4-ASA, 
m/z 194.0 to the m/z 150.0 for Ac-5-ASA; all analyses were in ESI negative mode with the ion 
spray voltage set up at -4500V. Under these conditions 5-ASA, Ac-5-ASA and 4-ASA were 
separated within 6 min. The analyst software version 1.6.1 was used for evaluation of 
chromatograms.  
Weighted linear regression (1/X) was applied for calibration in human plasma, GI fluid, 
and feces samples. Linearity of the calibration for both 5-ASA and Ac-5-ASA has been proven 
in human plasma over the range of 5 ng/mL to 2 µg/mL (r > 0.99), and in GI fluids and feces 
samples over the range of 50 ng/mL to 20 µg/mL (r > 0.99). Lower limits of quantification were 
identical with the lowest calibration levels. Inter-assay coefficient of variation (%CV) was 
between 2.5% and 11.7% for 5-ASA and between 2.6% and 5.6% for Ac-5-ASA, and the 
analytical recoveries of 5-ASA and Ac-5-ASA were respectively greater than 80.2% and 86.9% 
in plasma matrix. For human GI fluid and feces, the variation of the measured concentration 
from the nominal concentration was used as an indicator of the matrix effect. The results 
suggested that the matrix effect was insignificant for the %CV value was less than 15% at the 
given dilution factor. 
Data Presentation and Deconvolution 
Data analysis and visualization was conducted with the R 3.2.3 software package. 
Average plasma and GI concentrations were represented as mean ± standard error of the mean 
(SEM) based on all available samples. Pharmacokinetic parameters (Cmax, Tmax, and Area Under 
the Curve (AUC)) were reported as mean ± standard deviation (SD).  Individual plasma 
concentrations, GI concentrations, and pH values were represented using different colors. Feces 
were represented as an accumulation of collected endpoint. Individual feces portrayal was 
65 
 
depicted per individual case and sorted per endpoint. Parent vs. metabolite based on transit was 
depicted using the final value of accumulated collection. Statistics was not calculated due to 
limited sample size.  
Deconvolution was conducted using the Pheonix 64 Build 6.3.0.395 WinNonlin version 
6.3 by Pharsight. The two compartment PK model with a lag time and first order absorption was 
used to calculate the baseline pharmacokinetic characteristics for each individual. The model’s 
parameters were used to deconvolute the crossover study’s plasma data to best estimate total 
absorption.  
Results 
Demographics of Human Subjects 
As part of this study, 65 screening visits were performed.  There were 30 eligible subjects 
who participated in a total of 38 MR dosing:  24 subjects participated in one MR dosing, 4 
subjects participated in 2 MR dosing, and 2 subjects participated in 3 MR dosing.  
Study subjects were randomized to receive one of three mesalamine formulations during 
the MR dosing (IIA: Pentasa, IIB: Apriso, IIC: Lialda).  Out of 38 MR dosing conducted, there 
were 26 MR dosing successfully completed and 12 MR dosing that were discontinued.  After 
successful completion of at least one MR dosing, subjects were eligible to participate in an oral 
solution dosing and a total of 20 oral solution dosing were conducted (and all completed).  A 
summary of demographics of study subjects is presented in Table 5. 
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Table 5. Demographics of Study Subjects 
 
Study Arm 
Number of 
Subjects 
Completed 
Age 
(years) 
Body 
Mass 
Index 
(BMI) 
Sex Race Ethnicity 
 N 
Mean ± 
SD 
(Min-
Max) 
Mean ± 
SD 
(Min-
Max) 
Male Female Caucasian African-American Asian 
Not 
Hispanic 
or 
Latino 
Hispanic 
or 
Latino 
I  
Oral 
mesalamine 
solution  
20 33 ± 9 (18-51) 
26.1 ± 
4.2 
(17.8-
35.2) 
13 7 18 1 1 19 1 
IIA  
Pentasa 10 
38 ± 11 
(22-51) 
27.0 ± 
7.9  
(17.6-
45.2) 
7 3 8 2 0 9 1 
IIB  
Apriso 7 
37 ± 29 
(20-51) 
29 ± 8.2  
(21.3-
44.7) 
4 3 6 1 0 7 0 
IIC  
Lialda 9  
33 ± 8 
(25-51) 
28 ± 7  
(21.7-
43.9) 
7 2 7 1 1 8 1 
 
Crossover Phase (MR dosing) Study Discontinuations 
 
There were 12 MR dosing that were discontinued. For 5 subjects, the GI tube could not 
be advanced past the pylorus into the small intestine.  There were 3 subjects who requested 
removal of the GI tube, 1 subject who vomited during the tube insertion procedure, and 2 
subjects who vomited after study drug administration.  There was 1 subject who experienced an 
adverse event.  This subject experienced a vasovagal syncope event due to nerves and 
dehydration prior to the GI tube insertion procedure.  In addition, all subjects who had the tube 
successfully placed into the GI tract experienced mild sore throat.  This was an expected risk of 
the study and was resolved through the use of home remedies, including gargling with warm salt 
water and/or use of Ricola™ throat drops. 
 
Plasma Concentration After Administration for Three Mesalamine Drug Products 
 
Healthy human subjects were dosed with mesalamine solution (100 mg), Pentasa 
(500 x 2 capsules), Apriso (375 mg x 3 capsules) and Lialda (1200 x 1 mg tablet).  
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Mesalamine and its metabolite concentration in human plasma were measured using LC-
MS/MS (Figure 21).   
 
Figure 21. Average plasma concentrations observed for 5-ASA and Ac-5-ASA when 
administered a dose of 100mg mesalamine solution, 1000mg Pentasa, 1125mg Apriso, or 
1200mg Lialda. 
 
After ingestion of the mesalamine solution (100 mg), there is an immediate 
appearance of mesalamine (5-ASA) in the plasma by the first 15-minute time point. The 
Cmax (10.1 nM) was reached at Tmax (0.5 hr). The metabolite 5-acetyl-mesalamine (Ac-
5ASA) reached Cmax (8.6 nM) at 0.9 hr (Tmax). The AUC of Ac-5ASA was significantly 
higher than that of its parent (5-ASA) (20.4 vs 7.9 nM•h respectively). The terminal slope of 
the metabolite concentration vs. time curve was parallel to that of parent drug suggesting 
clearance of metabolite is formation rate limiting.  
Comparing the three mesalamine MR drug products, the plasma concentration of 
mesalamine and its metabolite are shown in Figure 21. Pentasa and Apriso had similar 
plasma AUC (normalized by dose given to 1g) of 0.040 and 0.049 nM•h/mg respectively, 
while Lialda had a lower AUC (0.035 nM•h/mg). Similarly, Pentasa and Apriso have a 
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similar Cmax of 8 and 9.8 nM respectively, which is significantly higher than that of Lialda 
(3.5 nM). However, Lialda had the longest Tmax (14.1 h) compared to Tmax (5.1 h) of both 
Pentasa and Apriso. The relative bioavailability of Pentasa, Apriso, and Lialda compared to 
the mesalamine solution is 0.52, 0.62, and 0.45 respectively (Table 6). 
 
Table 6. Mean parameters of systemic mesalamine (mean ± SD). 
 5-ASA Ac-5-ASA 
 Solution Pentasa Apriso Lialda Solution Pentasa Apriso Lialda 
Plasma (n) 20 10 7 9 20 10 7 9 
AUC0-n (nMh) 7.9±3.7 40.8±29.5 57.6±24.1 42.4±22.4 20.4±7.7 162±59.7 189±92.2 124.9±75.
4 
Cmax(nM) 10.1±4.8 8.0±8.4 9.8±4.8 3.5±2.3 8.6±3.9 11.6±6.3 16.8±9.6 5.8±2.6 
Tmax(hr) 0.5±0.1 5.1±2.8 5.1±1.5 14.1±12.3 0.9±0.4 6.1±2.4 5.9±1.6 16.2±12.3 
Relative 
Bioavailability 
 0.52 0.62 0.45     
 
 
The plasma concentration of mesalamine in each individual subject is shown in 
Figure 22. The data shows less variability in plasma concentration of mesalamine and its 
metabolite when the oral solution was administered. The three locally-acting mesalamine 
formulations exhibited large variability (mean Cmax of 3.5nM to 9.8nM).  
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Figure 22. Individual plasma concentrations observed for 5-ASA (left) and Ac-5-ASA 
(right) when administered a dose of 100mg mesalamine solution, 1000mg Pentasa, 1125mg 
Apriso, or 1200mg Lialda. Each color line represents one individual subject (note scale 
differences). 
 
In Vivo Gastrointestinal Concentration during Drug Dissolution after Administration 
for Three Mesalamine Drug Products   
 
In order to directly measure and compare in vivo drug dissolution in the human GI 
tract, healthy human subjects were intubated to obtain GI samples from four different 
locations in the GI tract: (stomach, duodenum, jejunum, and ileum).  Subjects were dosed 
with Pentasa (500 mg x 2 capsules), Apriso (375 mg x 3 capsules) and Lialda (1200 x 1 mg 
tablet).  The intestinal concentration of mesalamine (5-ASA) and its metabolite acetyl-5-
mesalamine (Ac-5-ASA) were measured using LC-MS/MS (Figure 23).   
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Figure 23. Average concentrations of 5-ASA and Ac-5-ASA in different regions of small 
intestine when administered a dose of 1000mg Pentasa, 1125mg Apriso, or 1200mg Lialda. 
 
 
The three mesalamine MR drug products exhibited very different release profiles. A 
pharmacokinetic summary is provided in Table 5.  Pentasa was the only formulation to have 
significant drug release in stomach where a high 5-ASA concentration (1500-2000 µM) was 
observed.  This high 5-ASA concentration range (1000-4000 µM) continued throughout the 
sampled GI tract from duodenum to distal jejunum. This suggests that Pentasa begans to 
release early in the stomach and that this release continues as the dosage form transits 
through the GI tract.  
Subjects with orally administered Apriso exhibited a very low 5-ASA concentration 
in stomach (<100 µM) indicating minimal drug release. In the duodenum, minimal Apriso 
appears after 4 hours. In the distal jejunum, Apriso appeared in large quantities (800 µM) by 
3 hours. Overall, the intestinal AUC and Cmax of 5-ASA in subjects that received Apriso was 
significantly higher in the distal jejunum region than any other sampled region. These data 
suggest that Apriso had limited release of 5-ASA in earlier regions such as in the duodenum 
with increasing drug release in the later regions of the small intestine.  
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In contrast, subjects that were orally administered Lialda had very low 5-ASA 
concentration from stomach (Cmax <0.7 µM) to distal jejunum (Cmax <8 µM) which suggests 
very minimal 5-ASA release from Lialda in the sampled regions of the small intestine.  
Although Pentasa had much higher concentrations of 5-ASA in the upper GI tract in 
comparison to Apriso, subjects that received Pentasa exhibited a slightly lower plasma Cmax 
and AUC for both 5-ASA and Ac-5-ASA than Apriso. Interestingly, more metabolite (Ac-5-
ASA) was detected in the GI tract of subjects with Pentasa than Apriso. This suggests that 
the early release of Pentasa may expose more of the drug to intestinal metabolism which 
would reduce the overall plasma exposure of 5-ASA in subjects. Alternatively, Apriso may 
have released more drug in the ileum region which in turn may have better systemic 
absorption than the regions of the GI tract sampled in this study.  
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Table 7. Mean parameters of gastrointestinal mesalamine concentrations (mean ± SD). 
 5-ASA Ac-5-ASA 
 Pentasa Apriso Lialda Pentasa Apriso Lialda 
Stomach (n) 7 4 9 7 4 9 
AUC0-8hr (µM•h) 6451±5706 157±134 2.0±2.9 93.5±188 10.9±10.1 1.2±1.9 
Cmax(µM) 2029±1430 72.2±30.4 0.6±0.5 32.2±56.1 4.6±2.1 1.1±2.0 
Tmax(hr) 3.2±2.0 4.8±1.3 3.7±1.6 6.4±1.1 5.0±1.5 4.1±3.1 
Duodenum (n) 7 6 4 7 6 4 
AUC0-8hr(µM•h) 6238±4654 828±916 3.5±2.9 1036±1087 435±583 3.6±3.5 
Cmax(µM) 2549±2097 829±1225 1.8±0.4 422±322 297±297 4.0±4.2 
Tmax(hr) 3.8±1.5 4.8±2.6 4.7±1.5 4.7±1.3 5.5±2.6 5.1±3.2 
Proximal Jejunum (n) 3 2 6 3 2 6 
AUC0-8hr(µM•h) 4867±2017 1698±323 7.4±13.0 3212±2010 825±953 1.8±1.9 
Cmax(µM) 2176±1403 1395±733 3.8±6.6 951±388 408±121 1.5±2.2 
Tmax(hr) 5±1.6 6.5±0.5 5.2±1.2 3.7±1.2 5.6±1.5 4.9±2.0 
Mid Jejunum (n) 5 3 4 5 3 4 
AUC0-8hr(µM•h) 7237±4598 378±608 27.9±53.2 4509±3508 357±368 16.7±24.1 
Cmax(µM) 2609±1441 169±211 15.6±27.8 1677±1404 169±139 9.1±9.6 
Tmax(hr) 4.7±1.5 5.4±1.3 5.4±2.5 4.8±0.7 6.4±1.0 5.2±2.6 
Distal Jejunum (n) 3 3 3 3 3 3 
AUC0-8hr(µM•h) 8456±7444 4923±8506 2.9±3.9 5048±5553 1225±2024 3.4±3.4 
Cmax(µM) 4495±2156 1434±8506 5.3±7.0 2422±2001 681±824 5.3±6.6 
Tmax(hr) 5.6±0.95 6±1.4 4.6±2.7 5.3±0.5 7±0 6.4±0.5 
 
 
We also note that the 5-ASA concentration in GI tract exhibited high variability. The 
drug concentration in each regions of small intestine of each individual subject is shown in 
Figure 24.  In each region of the small intestine, the concentrations varied at different time 
points due to variation in drug relese, dissolution, GI transit, metabolism, and absorption 
permeability. These factors contributed to the data variability. In addition, the different pH 
73 
 
values in different regions of the small intestine  likely contributed to the differences in drug 
release.   
 
Figure 24. Concentrations of 5-ASA and Ac-5-ASA in different GI regions for each 
individual subject when administered a dose of 1000mg Pentasa, 1125mg Apriso, or 
1200mg Lialda. Each colored line represents one individual subject. Red number indicates 
number of subjects sampled at specified location. 
 
 
There is a significant distinction between the three formulations in the early GI from 
stomach to jejunum. While the plasma exhibited a fairly similar overall drug exposure 
between Pentasa and Apriso, the concentrations in GI differ significantly. The pH triggered 
release of Apriso and Lialda is noted by the minimal exposure (157 and 2 nM•h, 
respectively) in the stomach. Pentasa's pH-independent exposure was an order of magnitude 
higher than Apriso (6451 nM•h) in the stomach. Notably, there was detectable exposure of 
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metabolite in the stomach for Pentasa, Apriso, and Lialda (93.5, 10.9, and 1.2 nM•h 
respectively).  
In general, the Cmax, AUC, and Tmax are as expected for these three delivery systems. 
Pentasa maintains a significant exposure (>4000 nM•h in all regions) throughout the 
measured regions in the GI tract suggesting extensive GI distribution. Apriso's delayed-
release mechanismis effective in delaying release in low pH but begins to release 
significantly by the distal jejunum. The low AUC value for Apriso in the mid jejunum (378 
nM•h) is likely due to the variation between subjects. Although Apriso has distinct delayed 
drug release from small intestine (until later Jejunum or early Illeum) in comparison with 
Pentasa, Apriso has similar exposure to that of Pentasa. This may suggest that Apriso has 
more drug release and absorption in ileum regions. Lastly, Lialda has a highly -pH-
dependent release mechanism with with very little mesalamine in small intestine regions 
(max 15.6 nM).  
In Vivo Dissolution of Mesalamine Drug Products in Stomach 
Subjects dosed with Pentasa had minimal 5-ASA concentration (84 µM) in the 
stomach at 1h after dosing which then increased to 1554 µM by the next time point (2h) and 
stayed consistently high until 7h. There was greater 5-ASA concentration in the duodenum 
(260 µM) at the 1h time point suggesting that transit and pH both affect mesalamine release 
and availability. From the 2h mark and onward, there is typically a high 5-ASA 
concentration (1800-2200 µM) throughout the sampled GI tract, suggesting that Pentasa 
distributes quickly throughout the small intestine (within 2h). It is surprising that the 5-ASA 
concentration was observed at high concentration until 7 hrs. Minimal amounts of 
metabolite (Ac-5-ASA) were found in the stomach (Cmax <360 µM) suggesting a low level 
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of metabolism in the stomach. In contrast, subjects with Apriso and Lialda had minimal 5-
ASA concentration (<75 µM) and Ac-5-ASA concentrations (<3 µM) from 1h to 7h.  
In Vivo Dissolution of Mesalamine Drug Products in Duodenum 
Subjects dosed with Pentasa had low 5-ASA concentration and had a continuously 
increasing 5-ASA concentration in the duodenum from 1h to 6h (259 to 1103 µM, 
respectively). The concentration then decreased to 787 µM by the 7h time point. The 
concentration of Ac-5-ASA in the duodenum after Pentasa administration was also low with 
a Cmin of 12 µM (1h) and a Cmax of 1590 µM (5h), suggesting an extensive metabolism in 
the duodenum.  
Apriso’s duodenal concentrations also increased gradually but were lower than 
Pentasa throughout the duration of the study, with a concentration of 0.2 to 876 µM for 1 to 
7 hours respectively. The duodenal Ac-5-ASA concentration after administration was below 
the limit of quantification by the first time point (1h). There was a presence by 5h with a 
concentration of 185 µM.  
Lialda’s duodenal concentration was extremely low for each time point, with a high 
of 1.1µM and a low of 0.3 µM. There was a very low concentration of Ac-5-ASA after 
dosing with Lialda with hours 1 to 3 being below the limit of quantification. The Cmax was 
at the final time point with a concentration of 5.6 µM.  
While individuals may vary for each administration of mesalamine, each formulation 
had a detectable amount of 5-ASA in the duodenum by 7h which was accompanied by some 
metabolite. Apriso had significantly lower release than Pentasa in the duodenum, and Lialda 
had very low mesalamine concentrations in the duodenum suggesting very minimal drug 
release. 
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In Vivo Dissolution of Mesalamine Drug Products in Proximal Jejunum 
Pentasa’s average 5-ASA concentration in the proximal jejunum was extremely low 
in the first hour (0.04 µM) followed by extremely high concentration (188 to 1868 µM) for 
subsequent time points (2 to 7h). The concentration of Ac-5-ASA mirrored the profile of 5-
ASA with an extremely low concentration (0.01 µM) in the first hour followed by a high 
concentration (324 to 921 µM) in the later time points. The concentration of metabolite was 
nearly equivalent to the parent suggesting there is extensive metabolism in this region.   
Apriso’s average 5-ASA concentration behavior in the proximal jejunum was similar 
to Pentasa’s. The first hour had an extremely low concentration followed by a high 
concentration at 2 hours (199 µM) where the highest value was at 7 hours (1046 µM). The 
Ac-5-ASA profile also reflected a similar concentration profile behavior. The Cmin value 
was at 2 hours (7 µM). From 3 hours onward, the concentration in the proximal jejunum 
ranged from 42 to 266 µM. The metabolite formation was more limited relative to Pentasa.   
Lialda’s average 5-ASA concentration behavior in the proximal jejunum was similar 
in profile to that observed in the duodenum. There was extremely limited release from 
Lialda tablets with a Cmax of 3.6 µM. This extremely limited release also explains the 
limited quantities of Ac-5-ASA with a Cmax of 1.2 µM at the 7 hour time point.  
In Vivo Dissolution of Mesalamine Drug Products in Middle Jejunum 
Subjects dosed with Pentasa had a low jejunal 5-ASA concentration (2 µM) at one 
hour indicating that transit was fast (within 1h). The concentration gradually increased to 
2141 µM at 4 hours and maintained a high concentration (1402 to 1713 µM) from 5-7 hours. 
The concentration of metabolite mirrored that of parent with low Ac-5-ASA concentration 
(12 µM) at one hour, increasing steadily to 1590 µM by 5 hours.  
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Apriso had a similar profile between the mid jejunum and the proximal jejunum. The 
concentration was low at 1 hour (0.8 µM) but increased to 14 µM by the second hour and 
maintained that range of concentration (12 to 73 µM) from 2 to 7 hours. Similar to Pentasa, 
the concentration of metabolite for Apriso also mirrored the parent. The concentration was 
low at 1 hour (0.2 µM) but increased to 35 µM by the second hour and maintained that 
range of concentration (22 to 155 µM) from 2 to 7 hours, suggesting high metabolism in 
mid jejunum.  
Lialda maintained its limited release in the mid jejunum reaching a Cmax of 7.4 at the 
5 hour time point. Similar to earlier regions, the concentration of Lialda was limited and 
only begins to be quantifiable by the five hour time point (5.2 µM).  
In Vivo Dissolution of Mesalamine Drug Products in Distal Jejunum 
Subjects dosed with Pentasa had very low concentrations in the first hour (0.2 µM) 
followed by a consistently high concentration (298 µM) in the second hour and gradually 
increasing to 3850 µM at hour 7. This suggested rapid drug transit to distal jejunum (early 
ileum) from 1 to 2 hours. This concentration profile was also reflected in the metabolite 
with a low concentration in the first hour (0.08 µM) followed by a concentration of 59 µM 
at the second hour and increased to 1899 µM by hour five.  
Apriso had a similar concentration profile to Pentasa where the first hour had limited 
concentration (0.3 µM) which quickly increased to 18 µM in the second hour and increased 
continually to 1419 µM at hour 4 where it maintained that concentration level for the next 
three hours. This concentration was somewhat higher than the concentration in the mid 
jejunum which likely reflected the higher pH levels seen in the distal jejunum. The parent 
profile was reflected in the metabolite profile, where the first hour showed limited 
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concentration followed by a concentration of 10 µM at the second hour and increased to 680 
µM by hour 7.  
Lialda again had limited release even in the distal jejunum with a Cmax of 7.3 µM at 
hour 7. The metabolite profile showed similar behavior with a Cmax of 7.5 µM at hour 7. 
All other time point concentration values were below 0.5 µM for both 5-ASA and Ac-5-
ASA.  
The 5-ASA concentration in GI tract exhibited very high variability. The drug 
concentration in each regions of small intestine of each individual subject is described in 
Fig 4.  In each region of the small intestine, the concentration varies at various time points 
due to drug transit, intestinal segment fluid mixing due to contractal activity, pH variation in 
drug release, metabolism, and absorption/permeability variation. These factors need further 
investigation. 
Composite Appearance Rate (CAR) of 5-ASA in Systemic Circulation for Three 
Mesalamine Drug Products. 
 
For modified release drug formulations, disintegration, dissolution, transit, and 
absorption will be complex. CAR is intended to capture these processes. Plasma concentration is 
the primary observed value of systemic presence that is a result of three components: absorption, 
clearance, and volume of distribution. These three components are the confounding variables that 
determine the final plasma profile that arises from a single dosing. Deconvolution is a predictive 
process that separates these confounding variables to isolate a certain aspect. In this case, 
deconvolution was used to isolate the absorption component to predict the necessary appearance 
of drug in the body to produce the resulting profile.   
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The plasma from each individual dosed with mesalamine solution was used to obtain 
a baseline pharmacokinetic parameters of 5-ASA. These parameters were then used as an 
individual basis to calculate the CAR of mesalamine appearance in the plasma vs time of the 
three mesalamine MR formulations (Figure 23). The motivation for performing individual 
deconvolution based on individual solution dosing plasma profiles was to minimize bias due 
to inter-individual confounding factors such as variation in distribution volume and 
clearance rates. The result is that CAR predicts the expected absorption rate of the drug 
from GI as a composite parameter of drug release, dissolution, transit, metabolism, and 
absorption from the entire GI tract.  
The three mesalamine MR formulations showed distinct CAR profiles, which 
indicate different release, dissolution, transit and absorption in different regions of GI tract. 
On average, individuals dosed with Pentasa had high levels of CAR immediately following 
dosing from 1 hour until about 10 hours, then decreased to minimal CAR after 12 hours. 
This is consistent with the high levels of 5-ASA found in the GI fluids. On average, those 
dosed with Apriso had low levels of CAR from 1 to 4 hours and high levels of CAR from 5 
to 10 hours, which decreased to minimal levels after 12 hours. This is consistent with the GI 
results where significant release occurs after either a sufficient time or pH was reached. 
Lialda showed minimal levels of CAR from 0-5 hours, then increased to medium levels 
from 5 to 12 hours, then decreased to further lower levels after 12 hrs. One of the 
individuals had a high gastric pH which explains the rapid CAR. Overall, the CAR of the 
three different mesalamine formulations mirrored the release and dissolution in the GI tract, 
therefore, the CAR may distinguish the differences among three different mesalamine MR 
drug products and be a useful BE determinate.   
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Figure 25. Composite Appearance Rate (CAR) vs. time plot of three mesalamine MR 
formulations in human subjects after administration of Pentasa (500 mg x2 capsules), 
Apriso (375 mg x3 capsules) and Lialda (1200 mg x1 tablet). Each colored line represents 
one individual subject. 
 
Gastrointestinal pH in Different Regions of Human Small Intestine  
The pH values were measured for each GI fluid sample and the results are depicted 
in Figure 26. In general, the pH is as expected for each region of the GI tract. Individuals 
that had a high gastric pH, high drug concentration in plasma and high drug release in 
stomach were observed, indicating that the high gastric pH had caused the dissolution 
process to start prematurely.  
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Figure 26. Individual pH values of human subjects obtained during GI fluid sampling. Each 
colored line represents one individual subject. 
Colon Content of Mesalamine Drug Products  
Pentasa (500 mg x 2 capsules) and Apriso (375 mg x 3 capsules) had a similar 
amount (0-200 mg range) of 5-ASA accumulation in feces despites differences in starting 
dose. Most individuals that were administered Lialda had a similar but slightly higher 5-
ASA accumulation (25-250 mg range). There were two individuals that were administered 
Lialda that had high amounts of 5-ASA in feces (430 and 820 mg). It is possible that the 
drug product did not experience either complete dissolution during transit and instead exited 
the body combined with feces. In addition, it is worth noting that most of the 5-ASA in the 
feces typically appears within 48 hours for most individuals. However, the high 5-ASA 
accumulation in feces for the two individuals appeared by the 24-hour collection point.  
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The accumulation of metabolite Ac-5-ASA in feces from 0 to 96 hours is similar in 
all individuals between the different formulations. Since the metabolism of 5-ASA in the GI 
from duodenum to distal jejunum is significant, the similarity of metabolite content present 
between the three formulation was unexpected.  
 
Figure 27. Accumulated 5-ASA and Ac-5-ASA in feces in individual subjects administered 
1000mg Pentasa, 1125mg Apriso, or 1200mg Lialda. Each color line represents one 
individual subject. 
 
Approximating Colonic Transit of 5-ASA from Fecal Appearance of Mesalamine Drug 
Products 
 
Colonic transit rate will significantly affect the accumulated drug and drug 
dissolution in colon. In this study, fecal samples data was limited as samples were only 
collected as designated time points. Since we were only able to collect feces samples every 24 
hours, the sample at 24 hour represents the total amount collected preceding the 24 hour mark. 
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Classification of colonic transit rate was estimated by two criteria. If largest drug amount was 
appeared in 24 hour feces samples (compared to 48 hours and 72 hours), these subjects were 
classified in fast transit group. If drug amount in feces at 24 hours is more than 20 mg, these 
individuals were classified to fast transit rate group even if more drugs appeared in feces at 48 
hrs. Similar method was used to classified average and slow transit. Based on this 
classification, the amount of 5-ASA collected at each time point was plotted in Figure 28. 
Three groups of subjects with fast, average, and slow colonic transit were observed. The fast 
transit group was considered when large amount of 5-ASA appeared in feces within 24 
hours. The average transit group was considered when large amount of 5-ASA appeared in 
feces from 24 to 48 hours. The slow transit group was considered when large amount of 5-
ASA appeared in feces from 48 to 96 hours.  
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Figure 28. Amount of 5-ASA in feces at different time points in subjects administered 
1000mg Pentasa, 1175mg Apriso, or 1200mg Lialda. Each colored line represents one 
individual subject. 
 
Correlation of Colonic 5-ASA and Ac-5-ASA content considering Colonic Transit  
The correlation of 5-ASA and Ac-5-ASA from colonic transit were plotted to show 
the 5-ASA metabolism difference in colon between fast and average colonic transit (Figure 
29) and difference between the three formulations (Figure 30). In Figure 29, individuals 
with average colonic transit exhibited a proportionate amount of parent 5-ASA and 
metabolite Ac-5-ASA. In contrast, individuals with fast colonic transit had a large amount 
of parent 5-ASA in feces, but lower amount of metabolite Ac-5-ASA in feces.  
In Figure 30, subjects with Pentasa and Apriso had a seemingly linear relationship 
between parent 5-ASA and metabolite Ac-5-ASA in the feces. In contrast, subjects with 
Lialda had more variable relationship between parent 5-ASA and metabolite Ac-5-ASA, 
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even if excluding the two cases with significantly high 5-ASA. However, overall presence 
of metabolite appeared to be within 100mg of the average regardless of parent drug 
presence. These data suggest that the three formulations can have a similar amount for both 
5-ASA (active) and Ac-5-ASA (metabolite) and that rapid transit may prevent Lialda’s 
MMX formulation from complete release.  
 
Figure 29. Correlation of accumulated 5-ASA vs Ac-5-ASA in feces in subjects with fast vs. 
average colonic transit after oral administration of 1000mg Pentasa, 1125mg Apriso, or 
1200mg Lialda. 
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Figure 30. Correlation of accumulated 5-ASA vs Ac-5-ASA in feces in subjects after oral 
administration of 1000mg Pentasa, 1125mg Apriso, or 1200mg Lialda. 
 
Discussion 
Previous understanding of in vivo drug release and dissolution has been limited to general 
recognition as a variable process that can be highly affected by various factors, such as 
solubility, dosage forms, fluid volume, pH, GI transit, buffer, and motility.  In order to predict 
the in vivo dissolution of a formulation, in vitro dissolution experiments are conducted to mimic 
drug release and dissolution. Since in vivo drug dissolution can differ significantly from in vitro 
studies, acquiring GI samples allows for a novel quantification of previously undefined 
variability to better understand in vivo drug release and dissolution.  
This is the first study to sample and compare in vivo GI mesalamine concentrations of 
three different formulations. There are currently five approved and one discontinued (Asacol) 
mesalamine oral drug products. Two of those are extended-release capsules (Pentasa, and 
Apriso), and three of those are delayed-release tablets (Asacol HD, Delzicol, and Lialda). 
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Knowing the limitation of the study that only upper GI fluid can be sampled and based on the 
plasma profiles of different mesalamine formulations, three MR products were selected for this 
study, namely Pentasa, Apriso, and Lialda. A comparison of PK parameters between this study 
and standard studies with no tube insertion were found to be comparable (data not shown), 
suggesting that GI tube insertion does not affect drug absorption. Additionally, samples acquired 
were sufficient to distinguish in vivo behavior differences between the three MR products despite 
being limited to the upper GI region (stomach to distal jejunum). 
In general, the release behavior found in the GI generally reflected expectations based on 
formulation design. The differences in formulation technologies used to manufacture Pentasa, 
Apriso, and Lialda were anticipated to have distinctly drug release profiles that would exhibit 
different plasma drug concentration profiles. Pentasa was expected to start drug release 
throughout GI tract to show early systemic appearance. Apriso with its pH resistant coated 
granules was expected to start releasing in the intestine with more than pH 6 environment 
resulting in a burst of systemic appearance. Lialda with its multimatrix design and pH 7 coating 
was not expected to release until further then followed by sustained release in later small 
intestine and colon. In this regard, the plasma profile generally reflected the expectations based 
on formulation design. 
Pentasa’s release was the earliest with several individuals exhibited a significant release 
of mesalamine in the stomach. The degree of release varied between individuals but release 
generally continued down the GI tract. This variability in release would be due to variation in GI 
transit or dissolution. Apriso’s release was significantly delayed compared to than Pentasa. Since 
Apriso has a pH sensitive coating, there were some individuals where mesalamine was found in 
the duodenum after 5 hours. For another Apriso dosed individual, mesalamine was found at high 
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concentrations (2500 µM) in the distal jejunum at 3 hours. This suggests that a pH dependent 
coating drug product’s release behavior is highly variable as a result of transit behavior. Lastly, 
Lialda with its multimatrix design and more stringent pH 7 coating had an extremely limited 
release of mesalamine in the sampled regions of the small intestine.  
Traditional characterization of residence time would approximate the stomach and small 
intestine average residence time to be about 30 minutes and 3 hours respectively. However, both 
Pentasa and Apriso had multiple individuals with significant amounts of release occurring in the 
small intestine after 4 to 7 hours when the drug would have been expected to be past the regions. 
Further, the unexpected observation of high 5-ASA concentration present in the stomach even 
after 7 hours indicates the GI tract transit of drug and drug products is complex and need further 
investigation  
The Composite Appearance Rate (CAR) was deconvoluted from plasma to quantify the 
drug product’s release, dissolution, transit, metabolism, and absorption in the GI tract. Each 
crossover arm trial deconvolution utilized the single arm solution dosing fitted to a two 
compartment model as an individualized basis. For mesalamine, two compartment models have 
been used to describe the plasma profile (94). Since each deconvolution calculation utilizes 
solution dosing as a baseline, CAR becomes particularly useful in distinguishing in vivo behavior 
of modified release formulations. The CAR of the three mesalamine MR formulations generally 
mirrored local release and dissolution from 1 to 7 hours in small intestine.  Mesalamine is known 
to be rapidly absorbed in the upper part of the gut but slow in the colon (95). A previous study 
suggested that intestinal transit rates may impact pharmacokinetics and efficacy of different oral 
mesalamine preparations (70). Therefore, the direct measurement of local GI drug levels and 
CAR analysis from plasma concentration-time profile may be used to compare bioequivalence 
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via plasma for locally-acting mesalamine products when drug dissolution profile in the GI lumen 
is required for efficacy in the small intestine.   
Subjects dosed with Pentasa had consistently high levels of CAR from 1 to 10 hours after 
administration which was consistent with the concentrations of mesalamine in the small 
intestine. Pentasa released 5-ASA from stomach to small intestine as directly measured in GI 
samples, which was consistent with high levels of composite appearance rate (CAR) 
deconvoluted from plasma drug concentration. Although significant variability was observed in 
both GI drug concentration and plasma drug concentration in subjects administered Pentasa, 
individuals with significant concentrations throughout the GI tract exhibited high drug 
concentration in plasma at early time points, while individuals with low drug concentration in the 
GI tract with delayed manner showed low and delayed plasma drug concentration. This 
variability would be due to either different drug release or dissolution in vivo or due to variation 
in GI pH, transit and motility.  
In contrast, the CAR of Apriso was at low levels for the first 3 hours. Apriso’s CAR 
suggested that it released 5-ASA in a burst like effect once environment pH is >6 at jejunum 
after 4 hours.  Apriso showed very little drug release in the stomach. There was a slight 
increment in drug release in the duodenum past four hours, which was benefited from Apriso’s 
pH resistant microgranules so an extended residence period would explain this behavior. In 
subjects who had drug release in jejunum from 3 to 7 hours also had a high plasma 
concentration. The high levels of CAR from 3 to 6 hours correlated with drug release in GI tract 
and plasma concentration, which suggested burst release of 5-ASA in small intestine regions 
with pH > 6 (either in jejunum or ileum).   Overall, the drug concentration in both the duodenum 
and jejunum for subjects dosed with Apriso were lower than that of subjects with Pentasa, but 
90 
 
plasma drug concentration in subjects with Apriso was higher from 4 to 8 hours than that of 
subjects with Pentasa. It was likely that the drug product transited past our last intestinal 
sampling point (i.e. distal jejunum to ileum) during this time. The CAR of Lialda suggested it 
had the most delayed release with most release occurring after twelve hours. Lialda had the 
lowest drug release in the small intestine as measured by GI concentration with low µM peak in 
comparison to more than 5000 µM seen with Pentasa. The CAR also showed minimal levels 
from 0-5 hrs and correlated with low plasma concentration. There was one individual with a high 
gastric pH causing an early release of mesalamine from Lialda. As such, this individual had the 
earliest and highest appearance of systemic mesalamine after administration of Lialda.  
Mesalamine oral drug products have demonstrated clinical efficacy in treating UC (82, 
83, 88, 89, 96, 97), which is the only FDA approved indication. However, it has been unclear 
whether different formulations of mesalamine will provide different clinical efficacy in treating 
disease in the small intestine. The study results here suggests that different mesalamine 
formulations will have different drug concentration in the small intestine and thus likely have  
different efficacy in  treating disease in small intestine (98).  
While both in vivo GI concentrations and CAR suggested that the three MR formulations 
have distinct in vivo dissolution profiles in small intestine, similar levels of both mesalamine and 
its metabolite were found in the feces across the three formulations despite different dosages. 
Since local presence of mesalamine is required for efficacy, this suggests that the three MR 
formulations may have similar effect in colon region. There was however, two subjects with a 
high accumulated amount of mesalamine in the feces by the 24 hour collect point. This data 
suggests that transit is likely rapid and that the tablet may not have fully dissolved before being 
expelled. Very interestingly, regardless the accumulated drug in the feces, all three formulations 
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generated similar amount of metabolite Ac-5-ASA in the feces. Since metabolism can only occur 
when 5-ASA is in solubilized form, the similarity in metabolite quantity may suggest similar 
release and dissolution between the three MR formulations in the colon region.  Therefore, the 
presence of mesalamine and metabolite in feces may also serve as a surrogate marker of efficacy 
in treating UC. The accumulation of drug and its metabolites in the feces may be used to 
compare the in vivo bioequivalence for locally acting drug products when drug dissolution is 
necessary for efficacy in the colon.     
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Chapter 5 Modeling Extend Gastrointestinal Residence Time Based on Mucoadherence of 
Modified Release Mesalamine (PENTASA) in the Human Gastrointestinal Tract 
 
 
High in vivo mesalamine concentrations in the stomach after 5 hours was discovered after 
quantification of human in vivo gastrointestinal (GI) samples of post-dose Pentasa (modified 
release formulation of mesalamine) (53). This observation runs contrary to the typical 
expectation that stomach empties rapidly in fasted state due to the zero-caloric nature of water, 
which was confirmed by in a clinical study observed a significant degree of gastric emptying 
within one hour of water dosing (28). As the in vivo dissolution process of modified release oral 
drug products is not well characterized with existing mechanistic models, developing that a 
model based explanation that reconciles the two juxtaposed clinical observations can provide 
valuable insight on gastrointestinal environment and future in vivo dissolution considerations.   
Mucus was identified as a potential contributor to gastrointestinal drug transport in a 
recent mechanistic fluid model of the GI (99). In general, the mucus layer in the human GI tract 
is an efficient physical and chemical barrier that acts as a shield against invading microbes (100). 
When foreign particles are introduced, these particles typically adhere to the mucus layer (101). 
While adhesion to mucus (mucoadhesion) is not fully understood, the mechanism has been 
proposed to a summation of attraction forces such as hydrogen bonding and van der Waals that 
promote entanglement between polymer and mucin. Many natural polymers and pharmaceutical 
ingredients such as carbomers, chitosan, starch, polymethacrylic acid, hydroxypropylcellulose, 
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hydroxypropyl methylcellulose, and sodium carboxy methyl cellulose exhibit these adhesive 
properties (102).  
Hydroxypropyl methylcellulose is one of the excipients used in the formulation of 
Pentasa that was specifically identified as having mucoadhesive properties. The 500mg capsule 
formulation of Pentasa is comprised of acetylated monoglyceride, castor oil, colloidal silicon 
dioxide, ethylcellulose, hydroxypropyl methylcellulose, starch, stearic acid, sugar, talc, and 
white wax (103). The capsule is intended as a carrier mechanism rather than a modified release 
function as the labeling for Pentasa notes that Pentasa can be administered in either capsule form 
or the capsule broken apart and sprinkled into yogurt or applesauce to be consumed immediately 
(104).  
Based on the formulation design and the use of hydroxypropyl methylcellulose, it is 
likely that Pentasa granules may be adhering to the mucosal layer in the GI, thereby increasing 
the residence time by slowing transit. Furthermore, the mean granule size of Pentasa is 1mm 
which further suggests ease of adherence with GI mucus that can vary in thickness from 50 to 
400µm based on physical relationship (105).This effect can explain the clinical observation of 
high stomach concentration of mesalamine at 5 hours. To evaluate the theory of whether mucosal 
adhesion play a large role in the high concentration of mesalamine in the GI tract, a simulation 
study using the Dynamic Fluid Compartment Absorption and Transport model was conducted to 
determine whether extended residence can explain the large concentration of mesalamine in the 
stomach after 5 hours.  
94 
 
Materials and Methods  
Computational Simulation 
A modification of the Dynamic Fluid Compartment Absorption and Transport model is 
detailed in the following expansions to capture the essential components of drug disintegration, 
dissolution, and absorption along with mucus interactions. The model consists of 162 nonlinear 
ordinary differential equations (ODE). The stomach is represented by five ODEs (solid dose, 
drug particles, dissolved drug, mucus, and fluid) with the small intestine represented by 150 
ODEs representing a 30-compartment model. Duodenum was recognized as compartment 1, 
jejunum being compartments 2-13 and the ileum being the remaining 14-30 compartments.  
An illustration of the proposed compartment model and avenues of transport is drawn in 
Figure 31. Matlab 2017a was used for both the simulation of model ODEs and the prediction of 
rate coefficient parameters. A fixed step ODE solver from the Simulink Package (ODE4) was 
used in 1s intervals. Visualized data graphics were rendered using Matlab’s plot packages. 
Pharmacokinetic fitting was conducted using Pheonix 64 Build 6.3.0.395 WinNonlin version 6.3 
by Pharsight.  
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Figure 31. Modified DFCAT model with mucus layer compartments 
Equations for Particle Transport with Mucoadherence Consideration  
The Pentasa granules were assumed to be released from the capsule delivery mechanism 
within 10 minutes. This was confirmed to be a likely outcome based on observations from in 
vitro dissolution tests (data not shown). As such, granules were assumed to be the primary 
undissolved form of mesalamine. In this case, the net transport of drug particles were assumed to 
be characterized by either the release from capsule, dissolution, mucus adherence, and GI transit 
(Equation 17). The equations from the Expanded Dynamic Fluid Compartment Absorption and 
Transport (EDFCAT) model were carried over with the addition of a mucosal adherence term. 
Mucosal adherence was assumed to be an irreversible process based on a first order mechanism. 
Transit of the mucosal adherence particles was assumed to occur at a slower pace.  
  BB1 = + 𝑘:e𝑃2`abMucoadherence − 𝑘1e𝑈2`abTransit	Forward + 𝑘1e𝑈2iTg`agbTransit	From	Previous (17) 
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Where 𝑘:e is the permanent binding coefficient of drug particle to the static mucus layer, 𝑃2 is 
the amount of drug as particles, 𝑘1e is the transit rate coefficient for mucoadhered drug particles, 
and 𝑈2 is the amount of drug that is adhered to the mucosal layer.    
Modeling Dissolution 
The dissolution of drug particles into solubilized form was represented by a single first 
order coefficient 𝑘B";;  (Equation 18). The use of a single first order to represent dissolution has 
been previously explored in Margolskee et al (61). Due to modification of the dissolution 
process, the traditional approach to determining relative dissolution rate based on 
thermodynamic solubility was not used.  
 B¦LB1 = −𝑘B";;(𝑡) ∗ 𝑃𝑛 (18) 
Where 𝑘B";;  is the first order dissolution rate coefficient and 𝑃2 is the amount of drug (particle 
form) in compartment 𝑛.  The temporal nature of 𝑘B";;(𝑡) was expected to correct for the true 
dissolution rate when performing mechanistic deconvolution.  
Evaluation Through Mechanistic Deconvolution 
Pharmacokinetic parameters were obtained through fitting of a 100mg solubilized 
mesalamine dosing in 240mL of water. Variations in the mucus adherence coefficient were 
tested. Mechanistic deconvolution to evaluate the system of interest by deconvoluting the 
average plasma profile observed for Pentasa. Model verification was based on comparison of 
plasma profile between simulation and experimental. Model validation was based on comparison 
of in vivo GI concentration profile between simulation and experimental. The in vivo GI 
concentration simulation results were considered the evaluation of mucosal adherence 
contribution to the model.  
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Results 
Pharmacokinetic parameters were determined based on a 2 compartment extravascular 
model using Winnonlin. The determined pharmacokinetic parameters are as follows: 𝑘T is 
0.017min-1, 𝑘TP is 0.009min-1, 𝑘PT	0.02min-1, and Vd/F=0.017L. The PK parameters were used to 
determine the absorption rate coefficient in the DFCAT approach. A range of absorption terms 
were tested and the term with the lowest residual difference between simulation and 
experimental plasma profile was selected. The absorption rate coefficient of mesalamine was 
determined to be 0.87 min-1. A graph of the fitted compartment model simulated using the 
DFCAT model is shown in Figure 32.  
 
Figure 32. Fitted pharmacokinetic model from 100mg solution dosing. 
 
Deconvolution Verification by Plasma Concentration Profile 
The deconvolution algorithm was set to ±0.5 ng/mL tolerance check at every six minutes. 
Based on this criterion, the algorithm could successfully determine a dissolution rate coefficient 
to simulate a plasma concentration profile similar to the experimental profile (Figure 33).  
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Figure 33. Simulated plasma profile used by mechanistic deconvolution 
 
The deconvolution algorithm could follow the obscure behavior of the plasma profile. 
There was minor over-estimation of the plasma profile at the Tmax of 180 minutes which can be 
reduced by reducing the time step from 6 minutes. However, this was not expected to play a 
major impact on the model results.  
Deconvolution Validation by in vivo Gastrointestinal Concentration Profile 
The simulated in vivo GI concentrations based on a determined 𝑘§e value of 0.045 min-1 
and a 𝑘1e value of 0.002 min-1 resulted in profiles that closely align with the general trend 
observed experimentally. A simulated Cmax of 2.9e5 ng/mL is similar to the observed 3.5e5 
ng/mL in the stomach. Similar observations where the simulated concentrations were in the same 
order of magnitude as the experimentally observed GI concentrations were observed in the 
duodenum and early jejunum. For the jejunal region, the simulation over predicted the early 
presence of mesalamine and underpredicted the later presence of mesalamine.  
99 
 
 
 
 
Figure 34. Comparison between predicted concentrations from deconvolution and experimental 
results. (top) Simulated vs average observed concentration profile. (bottom) Simulated vs 
experimental 90% geometric confidence interval. 
 
Simulated in vivo Dissolution Profile 
The rate and extent of regional GI dissolution was calculated based on the assigned 
compartments and shown in Figure 35. This simulation of mucosal adherence estimates roughly 
10% of the modified release formulation releasing in the stomach whereas the traditional 
expectation would be very limited. In contrast, the duodenal region was predicted to have limited 
release (~5%) due to the limited area and residence time of the drug in that region. A larger 
portion of the dissolution process was predicted ot occur in the jejunum and ileum region which 
aligns better with traditional expectations from both formulation and clinical observation where 
Pentasa is used to treat Chrohn’s disease.  
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Figure 35. Simulated in vivo dissolution profile from deconvolution results 
 
Discussion 
Modified release formulations have remained a challenge in drug development due to the 
complexity of the formulations (106).  Because MR formulations are design to release drug 
under specific conditions which can vary significantly in the body, it is difficult to stablish a 
relationship between in vitro and in vivo dissolution performance. While in silico models are 
often used to interpret in vitro data to provide a model based prediction of in vivo performance, 
obtaining accurate prediction of in vivo performance is often challenging. This can be attributed 
to the limited validation of the in vivo prediction for current computational models.  
The DFCAT model found that including a consideration for the mucus layer can explain 
the in vivo concentrations of fasted state phenol red (non-permeable) dosing (99). In this 
assessment, a mucus layer was found to contribute significantly to the local GI volume available 
for dissolution and absorption. When modeling the in vivo dissolution, it was found that gastric 
emptying contributed significantly to the transit of ibuprofen which reflects its properties as a 
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BCS Class IIa drug. This contrasts with mesalamine (BCS Class IV) where delayed gastric 
emptying would not be clearly reflected in the plasma profile. Additionally, the formulation of 
Pentasa was found to contain polymers that possess mucosal adherence properties. When 
simulated using the mechanistic deconvolution approach, the local GI concentration of 
mesalamine supports the idea that mucoadherence can extend the GI residence time of drug 
particles and thus explain the high concentrations in the upper GI.  
The simulation suggests that less than 50% of the total formulation based on the dose 
administered (1000 mg) was expected to be dissolved in the GI tract. The linical study reported 
an average between 100-200 mg of mesalamine recovered from feces which would suggest a 
local exposure of roughly 300-400 mg in the colon. This may be sufficient to invoke a 
pharmacodynamic response which would explain why Pentasa had demonstrated efficacious 
effect despite significant concentrations being observed in the upper GI tract over an extended 
period.  
The original purpose for conducting the mesalamine clinical study was to evaluate the in 
vivo dissolution based on concentrations as a reference for future regulatory guidance on the 
bioequivalence of locally acting GI drug products (107). Regulatory guidance on mesalamine has 
been of debate between in vitro dissolution, comparative pharmacokinetics, and clinical 
endpoints (108). The bio-adherence model of Pentasa dissolution suggests that not only is the 
plasma concentration profile a critical reference point but the formulation type and excipients 
used. The capsule containing granules is essential as a convenient delivery mechanism and the 
hydroxypropyl methylcellulose used in the formulation is essential to replicate any potential 
mucoadherence behavior.  
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While the model results and corresponding experimental observations appear to support 
the general hypothesis that mucoadherence is the explanation for the extended residence time of 
Pentasa in the GI tract, it is important to note that variations or delays in gastric emptying that 
was accounted in the ibuprofen simulation were not included when modeling mucosal adherence. 
As such, the extension of residence time for an oral drug product could likely be a combination 
of both gastric emptying variation and mucoadherence. The possibility of these additional 
interactions should be considered in future research and experiment design. 
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Chapter 6 Summary 
 
 
The purpose of this research was to develop an in silico method to quantify in vivo drug 
dissolution. Recent clinical studies had obtained post-dose gastrointestinal (GI) concentrations of 
different drug products in effort to quantify drug dissolution. However, concentration alone is 
indicative of neither rate nor extent of dissolution. Current in silico models were unable to 
reconcile the difference between the simulated and the clinically observed local GI concentration 
profile. As such, this research determined it was necessary to develop a new in silico approach to 
both quantify in vivo drug dissolution and relate to the experimentally observed local GI 
concentration.  
Local GI fluid volume plays a critical role in both the absorption of fluid and drug as well 
as driving the dissolution of drug product based on the concentration gradient. Based on this 
perspective, the characterization of GI fluid volume values used in current mechanistic oral 
absorption models was identified as insufficient to evaluate the local GI concentration. As such, 
the first step in developing a new in silico model was to establish a mechanistic GI fluid 
transport model. This model adapted a serial compartment based approach akin to existing 
mechanistic oral absorption models with a special consideration to local GI fluid volumes. The 
model created dynamic considerations for the local fluid volumes that included absorption, 
secretion, and transit.  
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The overall model performance was verified based on clinically observed fluid quantity 
over time data. MRI images collected the quantified total content of free flowing liquid in the GI 
via 3 dimensions. To ensure the model adapted the most physiologically representative fluid 
volumes for use, it was noted that the study observed large regions with little to no fluid 
observed. Upon confirming the MRI methodology, it was noted that a vicious fluid such as the 
mucus layer that lines the GI wall would not be detected by the MRI. As it would not be feasible 
to remeasure the mucus layer volume, an approximation was made for the total volume of mucus 
based on physiological estimations to provide a quantified volume for each compartment that 
may contribute to both dissolution and absorption.  
The resulting mechanistic model simulated the intake of water into the stomach and the 
corresponding transport over time. The simulation volume over time results were found to be 
similar to the experimental results. To validate this model, an additional simulation was 
conducted with the dosing of phenol red, a non-absorbable marker. This additional data was the 
result of another separate clinical study which dosed volunteers with 240mL of phenol red (100 
µg/mL). The simulation results were found to again to be similar with experimentally observed 
concentration profiles especially in the earlier GI tract. This confirmed the reasonableness behind 
the assumption of a mucus layer contributing to local GI fluid volume.  
To model in vivo dissolution, the mechanistic fluid model was expanded to include 
considerations for drug transit, disintegration, and dissolution analogous to current mechanistic 
model. A deconvolution method was adopted to reverse calculate the requisite in vivo drug 
dissolution to obtain the plasma profile. Data to evaluate in vivo dissolution came from an 
intubation based clinical study where healthy human fasted volunteers were dosed with 800mg 
immediate release tablet formulation of ibuprofen. This clinical study obtained the in vivo 
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ibuprofen concentration from stomach, duodenum, proximal jejunum, and middle jejunum. In 
this model, systemic circulation was defined by the traditional two-compartmental 
pharmacokinetic (PK) model where the PK parameters could be determined by fitting to plasma 
concentration profile from an 800 mg dosing of ibuprofen by infusion. The established PK 
parameters were then used to determine the absorption rate constant from a 420 mg solution 
dosing of ibuprofen using the established mechanistic fluid model.  
Additional model considerations accounted for ibuprofen’s BCS Class IIa nature. The 
clinical study observed plasma profile behavior reminiscent of a rapid increase in dissolution and 
therefore absorption. Given that ibuprofen has a high solubility level after reaching the duodenal 
pH levels, a significant increase in plasma profile was associated with a stochastic gastric 
emptying event. With these considerations in place, the resulting model estimated a dissolution 
profile for each clinically observed plasma profile with the resulting plasma profile was within 
±1 µg/mL of the observed plasma profile. To validate this model, the distribution of simulated 
GI ibuprofen concentration over time was compared with the distribution of experimentally 
observed concentration over time. The resulting observed profiles were similar in trend and 
approximated the general range of concentration values within an order of magnitude.  
This implementation of the mechanistic deconvolution approach was also applied to 
model the in vivo dissolution of a controlled release mesalamine formulation (Pentasa). A similar 
approach was taken where pharmacokinetic parameters were determined, the mechanistic 
deconvolution algorithm was utilized to predict in vivo dissolution rate, and the simulation 
results evaluated based on in vivo GI concentrations. Unlike ibuprofen however, mesalamine is a 
BCS class IV compound and not expected to be solely limited by solubility. As mesalamine was 
also clinically observed to exhibit high concentrations in the stomach after 7 hours, 
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mucoadherence of the formulation was identified as possible explanation for the extended 
residence time.  
Specifically, hydroxypropyl methylcellulose was identified as an excipient with 
mucoadherence properties. When consideration for mucosal adherence was included in the 
mechanistic oral absorption model by establishing additional compartments where particles 
would “attach” to the mucosal layer and then transit forward slowly, the model simulated in vivo 
GI concentrations that were very similar amongst the GI tracts sampled. In addition, the 
increased residence time that resulted from the consideration of mucosal adherence ensured a 
continued release in the upper GI which resulted in the model mimicking the high in vivo GI 
concentrations after seven hours.  
In conclusion, the simulation results suggest that quantification of GI fluid and 
consideration of GI mucus volumes are critical to correctly predicting the dissolution and 
absorption of oral drug products. Furthermore, considerations of gastric emptying and/or 
mucoadherence of formulations may be essential to correctly predicting the rate and extent of in 
vivo dissolution as well as the subsequent plasma profile. To continue improving model based 
prediction of in vivo dissolution, additional clinical studies the quantify GI fluid volume in 
different states (fasted/fed), quantify the presence of the mucus layer, and visual based 
observation of gastric residence or mucoadherence via ingestible camera pills can be used to 
further validate the developed model.  
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